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SOMMARIO 
L’emergere ed il rapido diffondersi di batteri resistenti agli antibiotici è stato 
un importante e crescente problema di salute pubblica a livello mondiale negli 
ultimi vent’anni. 
Attualmente gli Enterobatteri resistenti ai β-lattamici, particolarmente quelli 
resistenti ai carbapenemici, rappresentano uno dei principali motivi di 
preoccupazione a livello internazionale, poiché la loro resistenza è spesso mediata 
da plasmidi e quindi facilmente trasmissibile e provocano epidemie nosocomiali 
con elevato tasso di mortalità. 
Prioritario è che i laboratori di microbiologia clinica, soprattutto in ambito 
ospedaliero, identifichino rapidamente i pazienti colonizzati da ceppi batterici 
multiresistenti, particolarmente i produttori di carbapenemasi, così da limitarne la 
diffusione, prevenire episodi epidemici ed indirizzare rapidamente la scelta di una 
terapia appropriata. 
La ricerca si muove, quindi, verso lo sviluppo di nuovi strumenti diagnostici 
che permettano di individuare rapidamente i ceppi batterici multiresistenti in 
campioni clinici, riducendo drasticamente il tempo di refertazione.  
 
Obiettivo del nostro studio è stato validare l’utilizzo del sistema MALDI-
TOF MS (Matrix Assisted Laser Desorption Ionization Time-of-Flight Mass 
Spectrometry) come metodo rapido per identificare Enterobatteri produttori di 
carbapenemasi, confermando la correlazione tra un caratteristico picco MS 
(11,109Da±8) e la produzione di Klebsiella pneumoniae carbapenemasi (KPC).  
Sono stati ricercati, inoltre, altri picchi correlati alle carbapenemasi NDM 
(New Delhi metallo-β-lactamase) e VIM (Verona integron–encoded metallo-β-
lactamase) e si è valutato l’utilizzo del sistema MALDI-TOF MS per individuare 
rapidamente focolai epidemici. 
 
 A questo scopo abbiamo utilizzato campioni clinici selezionati, produttori di 
KPC e campioni di controllo sensibili ai carbapenemici o resistenti a causa di altri 
meccanismi o per produzione di altri enzimi (NDM e VIM). La presenza del picco 
in esame nel 98% dei ceppi produttori di KPC (225/230) e l’assenza dello stesso 
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nei campioni di controllo, ha confermato la stretta correlazione tra produzione di 
KPC e presenza del picco di 11,109Da nello spettro MALDI-TOF MS. 
 Abbiamo, inoltre, verificato la possibilità di utilizzare la ricerca del suddetto 
picco durante la routine diagnostica, eseguendo l’analisi degli spettri MALDI-TOF 
MS su 183 campioni isolati durante lo screening MDR. La presenza del picco di 
11,109Da negli spettri del 98% dei ceppi (129/132) con test Carba NP positivo, 
produttori di KPC, conferma la possibilità di utilizzare l’analisi degli spettri 
MALDI-TOF MS come metodo rapido di screening dei ceppi produttori di 
carbapenemasi, economico ed adatto ad investigare un elevato numero di campioni. 
In questo modo si possono riservare i più costosi e complessi metodi molecolari 
solo ai ceppi che mancano del picco pur essendo positivi ai test fenotipici.  
 
Non abbiamo, invece, individuato altri picchi correlati alla produzione di 
carbapenemasi diverse dalla KPC (NDM e VIM), analizzando gli spettri di 15 ceppi 
di Enterobatteri produttori di NDM e 23 ceppi di Enterobatteri e 13 di P. aeruginosa 
produttori di VIM. Questo risultato sembra essere in linea con la molteplicità di 
plasmidi che portano i geni che codificano per questi enzimi. 
 
Infine l’utilizzo della MALDI-TOF MS per determinare la clonalità di ceppi 
batterici non è risultato particolarmente promettente, rispetto alla Pulsed-Field Gel 
Electrophoresis (PFGE) con cui l’abbiamo comparata, utilizzando 44 ceppi di K. 
pneumoniae isolati durante un’epidemia. Il problema potrebbe essere dovuto al 
software attualmente in uso. 
 
Il sistema MALDI-TOF MS, si conferma, quindi, uno strumento valido per 
identificare rapidamente ed in modo accurato ceppi batterici produttori di 
carbapenemasi, il che rappresenta un importante passo avanti nella diagnostica 
clinica. 
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ABSTRACT 
  
The occurrence and rapid spreading of multi-resistant bacteria is an important 
issue of public health, which is increasing worldwide over the last two decades. 
β-lactams-resistant Enterobacteriaceae, with particular reference to 
carbapenems, are actually one of the main concerns at international level, as their 
resistance is often plasmid-mediated, thus rapidly spread and often associated with 
hospital outbreaks with high rates of mortality. 
Clinical microbiology labs, especially in hospital settings, require to quickly 
identifying patients who carry multi-resistant bacterial strains, especially 
carbapenemase producers, in order to contain their spreading, preventing epidemic 
outbreaks and rapidly address proper pharmacological therapy.  
Research is moving towards development of new diagnostic tools to speed up 
identification of multi-resistant strains in clinical specimens, thus drastically 
shortening the time necessary to obtain analysis reports. Rapid identification of 
colonized patients, in fact, is the only valid strategy to curb epidemic spreading, 
mainly when is due to plasmid-mediated resistant determinants.  
 
The objective of this study is to validate the use of Matrix Assisted Laser 
Desorption Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) for 
quick identification of carbapenemase-producing Enterobacteria strains, thus 
confirming that a characteristic MS peak (11,109Da±8) is related to Klebsiella 
pneumoniae carbapenemase (KPC) production.  
Moreover, the presence of other peaks related to NDM- (New Delhi metallo-
β-lactamase) and VIM- (Verona integron–encoded metallo-β-lactamase) 
carbapenemases as well as the evaluation of MALDI-TOF MS as a tool to quickly 
identify epidemic hotbeds, were investigated. 
 
At this aim, selected clinical samples KPC-producing and control samples 
carbapenem-susceptible or carbapenem-resistant through other resistance 
mechanisms or producing hydrolytic enzymes other than KPC (NDM and VIM) 
were analyzed. 
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The presence of the 11,109Da peak in 98% (225/230) of the KPC-producing 
strains compared to the controls, which lacked the peak, confirmed strong 
correlation between KPC production and the presence of the 11,109Da peak in 
MALDI-TOF MS spectrum. 
The reliability of the method was also verified by searching for this specific 
peak during routine workflow, analysing the MALDI-TOF MS spectra of 183 
patient samples isolated during multidrug-resistant (MDR) screening. The positive 
correlation between the presence of 11,109Da peak and Carba NP test confirmed 
the reliability of MALDI-TOF MS analysis as rapid and inexpensive screening 
method for carbapenemase-producing strains, apt to investigate a high number of 
samples in KPC-endemic context. In this way, the molecular methods more 
expensive and difficult to perform during routine workflow, can be used to resolve 
discrepant strains only.    
 
 We did not find, instead, any correlation between other peaks and 
carbapenemases other than KPC, namely NDM and VIM, through the analysis of 
the spectra of 15 NDM-producing Enterobacteria strains and 23 Enterobacteria 
strains and 13 P. aeruginosa strains VIM producers. This result is in line with the 
high number of plasmids harboring the genes codifying for these enzymes. 
 
Finally, the use of MALDI-TOF MS was found not particularly promising as 
tool to identify clonal relationship between bacterial strains as compared to Pulsed-
Field Gel Electrophoresis (PFGE) using 44 K. pneumoniae strains isolated during 
an epidemic outbreak. Drawbacks could be related to the current software. 
 
We therefore confirmed MALDI-TOF MS system is a good tool to quickly 
and accurate identifying carbapenemase-producing bacterial strains, that represents 
effective advancement in clinical diagnostic.  
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INTRODUCTION 
 
1. Antibiotics 
Antibiotics are compounds of natural origin produced by microorganisms, 
used to treat and prevent bacterial infections. Since their introduction, the 
occurrence of many illnesses and the number of deaths from infectious diseases has 
been greatly reduced with a consequent extension of life expectancy. 
In nature, the role of molecules with antibacterial activity is not fully 
understood. Bacteria produce antibacterial compounds that allow survival and 
provide competitive advantage against other microorganisms. Effectiveness 
depends on the level of concentration. At high concentration, they have killing 
effects against bacteria whilst at sub-lethal concentrations they have growth-
inhibitory effects. At sub-minimum inhibitory concentrations, however, these small 
signal molecules intervene in chemical communication, as happen in the quorum 
sensing [1], they can be modulators for gene transcription [2] or function as 
pheromones that stimulate bacterial conjugation. [3]   
The use of natural substances to fight illnesses was already known two 
thousand years ago in Egypt, Greece and China. However, it is the discovery of 
penicillin by Sir Alexander Fleming in 1928 that marks the beginning of the 
antibiotic era. [4] Chemotherapy takes its roots from the work of Paul Herlich (1854-
1915), who advanced the idea of selective toxicity. It becomes a real science in 
1935, when Dogmack launched Prontosil, a sulphanilamide derivative for the 
treatment of streptococcal infections. In the late 30s Chain purified and stabilized 
penicillin, allowing its clinical use which began in a massive way during the Second 
World War. A further milestone is represented by Wakeman’s 1944 discovery of 
streptomycin which was later used for tuberculosis treatment. [5] When the 
industrial production of antibiotics started, it was thought that the battle against 
infectious diseases was won. However, as early as 1945, Alexander Fleming 
reported the existence of penicillin-resistant microorganisms and raised the alarm 
regarding antibiotic overuse. [6] Thereafter, antibiotic resistance quickly became a 
serious clinical concern.  
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From the late 1960s through the early 1980s new antibiotics were looked 
for in order to solve the problem. Tetracyclines, chloramphenicol, cephalosporins, 
carbapenems were marketed but it was soon realized that the development of 
resistance is faster than the discovery of new antibiotics. As a result, over a few 
decades, resistance to all antibiotics that have been developed was observed. [Fig. 
1] The idea that synthetic molecules such as fluoroquinolones can be immune to 
the development of resistance, had failed.  
 
 
 
 
Fig. 1 Developing Antibiotic Resistance: A Timeline of key events based upon early 
reports of resistance in the literature. (From: CDC-Centers for Disease Control 
and Prevention) [7] 
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Based on the huge number of microorganisms and still unknown chemical 
compounds existing in nature, new antibiotics could be developed by using 
bioengineering and new genetic methods. [8] However, the processes are not 
necessarily economically beneficial for pharmaceutical industries and investments 
in this field are limited. There are very few compounds with new mechanisms of 
action under development and this represents a particularly evident problem for the 
treatment of infections caused by multidrug-resistant Gram-negative bacteria. [3] [9] 
[10] Since the year 2000, five new classes of antibiotics have been marketed: 
oxazolidinones (Linezolid), lipopetides, pleuromutilins, tiacumicins and 
diarylquinolines, but they are all active only against Gram-positive bacteria. [11] All 
other antibacterial compounds have just been variations of the existing ones, and 
the emergence of resistance does not spare these either.   
Antibiotics are classiﬁed into different chemical classes and deﬁned 
according to their target of action: a) cell wall synthesis, b) protein synthesis, c) 
DNA or RNA synthesis, d) metabolic pathway, e) cell membranes. [Fig. 2] 
 
Fig. 2 Mechanisms of action of antibiotics: Inhibition of cell-wall synthesis, DNA and RNA synthesis, 
protein synthesis and metabolic pathways. (Modified from Coates et al. 2002) [12] 
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They are defined as bactericidal when they cause bacterial death and 
bacteriostatic if they inhibit cell growth. 
 
a) Antibiotics that affect cell wall synthesis are the class of antibiotics most 
widely used. They have a bactericidal effect since they induce cell death by 
inhibition of the peptidoglycan biosynthesis, the major constituent of the bacterial 
cell wall. The structural integrity of the cell envelop is damaged and the 
microorganism cannot survive.  
Cell wall synthesis is inhibited by β-lactams (penicillins, cephalosporins, 
carbapenems, monobactams) and glycopeptides. The β-lactams inhibit the 
transpeptidases enzymes, known as penicillin binding proteins (PBP) preventing 
the peptidoglycan units cross-links. Glycopeptides prevent transglycosylase and 
transpeptidase activity binding with peptidoglycan units. [13] 
• Penicillins (penicillin, oxacillin, 
methicillin, amoxicillin, etc.) have a common 
backbone that is 6-amino-penicillanic acid [Fig. 
3] with various acyl radicals. Benzilpenicillin or 
Penicillin G is a natural compound produced by 
mould Penicillium chrysogenum. Penicillins are active against only a narrow 
spectrum of Gram-positive bacteria, e.g. S. pyogenes, S. pneumoniae, Enterococci 
and sensitive-strains of S. aureus, because they fail to penetrate the outer membrane 
of most Gram-negatives. Semisynthetic drugs such as aminopenicillins were 
developed later with activity also against some Gram-negative bacteria (Neisseria, 
Haemophilus), piperacillin is also active against Pseudomonas aeruginosa and 
methicillin is active against β-lactamase-producing strains. [5] 
• Cephalosporins (cephalothin, cefuroxime, 
cefotaxime, ceftazidime, cefepime, etc.) have the 
7-aminocephalosporanic acid as common 
backbone. [Fig. 4] The first compound isolated 
from Cephalosporium acremonium was 
Fig. 3 Penicillins chemical structure. 
Fig. 4 Cephalosporins chemical structure. 
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Cephalosporin C. In 1964, the clinical use of cephalothin began. Then other 
semisynthetic compounds were developed and classified as generations I to V. 
Compared to penicillins, these compounds have a wider activity against Gram-
positive and Gram-negative bacteria. Moreover, IV generation cephalosporins are 
active also against P. aeruginosa. Cephalosporins are the most clinically prescribed 
class because of their strong activity and high tolerability. [5]  
• Carbapenems (imipenem [Fig. 5], 
ertapenem, doripenem, meropenem) are 
derivatives of thienamycin, an antibiotic 
produced by Streptomyces cattleya. They are 
active against a broad spectrum of bacteria, 
including Gram-positive and Gram-negative, 
aerobes, anaerobes bacteria and P. aeruginosa. This very important group 
represents the last resort in treatment of infections caused by bacteria resistant to 
other β-lactams and are used in a wide range of severe infections including 
bloodstream infections, hospital-acquired, complicated urinary and respiratory 
infections, bone and soft tissue infections, obstetric and gynecologic infections. [5]                     
• Monobactams are monocyclic β-lactams 
isolated from Chromobacterium violaceum [Fig. 6]. 
Only Aztreonam, a synthetic derivative, is approved 
and marketed. It is active only against Gram-negative 
and aerobic bacteria. [5]  
• Glycopeptides (vancomycin, teicoplanin) are 
active against Gram-positive bacteria, aerobe and 
anaerobes. Vancomycin [Fig. 7] was the first 
compound of this class to be isolated from 
Amycolatopsis orientalis and patented for clinical use 
against penicillin-resistant S. aureus. Teicoplanin was 
isolated in 1978 from Actinoplanes teichomyceticus, its 
activity is similar to that of vancomycin. [5] 
 
Fig. 6 Aztreonam chemical 
structure. 
Fig. 5 Imipenem chemical structure. 
Fig. 7 Vancomycin chemical 
structure. 
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b) Antibiotics that inhibit protein synthesis interact with ribosomal 
subunits. They include aminoglycosides (amikacin, gentamicin, kanamycin, etc.) 
and tetracyclines [Fig. 8] that are able to inhibit ribosome subunit 30S by the 
alteration of the complex mRNA/aminoacyl-tRNA at the ribosome, causing 
mismatching and protein mistranslation, or blocking the access of aminoacyl-
tRNAs to the ribosome. Protein synthesis inhibitor also include macrolides 
(azithromycin, clarithromycin, erythromycin, etc.), chloramphenicol, lincosamides 
(clindamycin) and oxalidinones (Linezolid) [Fig. 9] that interact with 50S subunit 
blocking initiation of protein translation or translocation of peptidyl-tRNAs. [13]  
                      
 
Most of these compounds, e.g. tetracyclines and aminoglycosides are 
produced by Streptomyces species or related soil bacteria.                                                                                                                                                            
• Aminoglycosides are bactericidal compounds active against Gram-negative 
bacteria and some compounds have additive or synergistic activity with other β-
lactams also against Gram-positive cocci. [5] 
• Tetracyclines, Chloramphenicol, Lincosamides are bacteriostatic, active 
against Gram-positive and Gram-negative bacteria.  
 
c) Antibiotics that interfere with the 
nucleic acid synthesis are fluoroquinolones 
(ciprofloxacin [Fig. 10], levofloxacin, moxifloxacin, 
norfloxacin, etc.) and rifamycins (Rifampin). They 
are bactericidal with broad antibacterial spectrum. 
• Fluoroquinolones target DNA gyrase and topoisomerase IV, enzymes 
involved in DNA transcription and replication. They are derivatives of nalidixic 
Fig. 10 Ciprofloxacin chemical 
structure. 
Fig. 9 Linezolid chemical structure. Fig. 8 Tetracycline chemical structure. 
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acid introduced in 1960s to treat urinary infections. Their broad spectrum of 
activity, particularly against Gram-negative bacteria, makes their use very common 
for treatment of urinary, respiratory, gastrointestinal, and sexually transmitted 
infections. [13] 
• Rifamycins target RNA polymerase which performs RNA synthesis. The 
first compound was isolated from Streptomyces mediterranei in 1950. They are 
active against many bacterial species and are used in the treatment of tuberculosis. 
[13] 
 
d) Antibiotics that interfere with metabolic pathways: sulfonamides are 
among the first antibiotics used in the 1930s. Their action interferes with folic acid 
synthesis. Usually it is used combined with trimethoprim that increases its activity 
in urinary tract infection, but it is also used in malaria treatment or against 
Pneumocystis. 
 
e) Antibiotics that act on bacterial cell membranes have a lower selective 
toxicity than the previous target and their action can affect eukaryotic cell also.  
• Daptomycin, produced by Streptomyces roseosporus is able to permeabilize 
membranes containing phosphatidylglycerol, a lipid plentiful in the bacteria cell 
membranes but not in human cell membranes. It is active against only Gram-
positive bacteria, because it fails to penetrate the outer membrane of Gram-
negatives.  
• Polymyxin B, produced by Gram-positive bacterium Bacillus polymyxa, an 
antibiotic known for a long time, no longer used because of its toxicity, but now it 
has reappeared and is being used for the treatment of multi-resistant Gram-negative 
bacteria, such as P. aeruginosa, Enterobacteriaceae, Acinetobacter and Colistin 
(Polymyxin E) product of Bacillus colistinus. These compounds are able to 
penetrate into the bacteria cell membranes and disrupt them by interaction with 
phospholipids. They are also able to interact with lipopolysaccharide by interfering 
with endotoxin action. [5] 
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2. Antibiotic resistance 
 
2.1 Causes and effects 
After a first enthusiastic period in which everyone thought the fight against 
infectious diseases was won and when research and production of antibiotic 
compounds increased, the truth about resistance appeared and it turned out to be a 
great threat. 
Antibiotic resistance is a natural phenomenon. Because antibiotics are 
natural compounds produced by microorganisms, bacteria encounter them regularly 
and over millions of years they have adapted to these drugs, making them less 
effective. [8] Also, it is natural that antibiotic-producing bacteria carry gene 
encoding for resistance to the antibiotics that they produce and it is hypothesized 
that many resistance genes, principally encoding for antibiotic hydrolyzing 
enzymes, for example extended spectrum β-lactamase CTX-M [10], but also target-
protecting enzymes, or efflux-pumps, may originate from Actinomycetes. [14] 
Furthermore, it was observed that often resistance genes are arranged on bacterial 
chromosome in a cluster with genes for biosynthesis of antibiotics. [15] 
We define intrinsic resistance, that of microorganisms which do not have an 
antibiotic target or of a bacterial cell which is impermeable to antibiotics. That is, 
species-speciﬁc and independent from antibiotic misuse. For example, the cell wall 
structure of Gram-negative makes them resistant to hydrophobic molecules such as 
macrolides, that can’t pass through outer membrane. [16] 
Bacteria can also show an acquired resistance when they become resistant 
through mutation [17] or acquisition of genetic elements, after exposition to 
antibiotic. Acquired resistance can be passed by vertical transmission to daughter 
cells during binary division or by horizontal gene transfer, in this case the 
transmission is also possible between different species of bacteria. Gene exchange 
for conjugative transmission is frequent in nature much more than mutations, a very 
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infrequent event (about 1 per 107 to 1010 cells), [10] probably used to regulate 
communication and molecules signalling production. [1]   
Resistance genes can encode for various resistance strategies. Resistance to 
one specific agent corresponds to resistance to a whole class and cross-resistance 
to other classes with the same action mechanism. If several different mechanisms 
are present they result in Multidrug-resistance (MDR), or Extensively-drug 
resistance (XDR) until Pandrug-resistance (PDR) when all antibiotics are 
ineffective. [18] β-lactams, glycopeptides and fluoroquinolons are the classes most 
affected by resistance.  
The transmission of resistance genes and the spread of antibiotic resistance 
witnessed an acceleration with the beginning of large scale clinical use of 
antibiotics and especially with their incorrect use, such as unnecessary prescription; 
or purchase without prescription; improper dosage and duration; empirical use of 
wide spectrum drugs; massive use in livestock and the environment. [8] Antibiotic 
use at sub-inhibitory and sub-therapeutic concentrations, in fact, can kill sensitive 
bacteria and select resistant strains that then multiply. Moreover, it increases the 
virulence and the interaction with host immune response. Also, genetic 
modifications are promoted and changes in the expression of bacterial resistance 
genes. [3] [17] 
Imprudent use of antibacterial products, also sold for hygienic or cleaning 
purposes and the overuse of antibiotics as growth promoters in livestock increases 
the problem for the mobilization of resistance genes from environmental and 
animal’s bacteria to commensal and pathogenic strains in humans through water 
and food. [16] [19] Therefore we use the concept of resistome, which is the set of genes 
that are directly or indirectly involved in antibiotic resistance. [10] [20]  
The idea that antibiotic resistance is a new phenomenon, therefore, is not 
true. Genes encoding resistance to β-lactams, tetracyclines and glycopeptides 
antibiotics were found in permafrost 30,000 years-old. [20] [21] Resistance is a natural 
evolution enhanced by misuse of antibacterial, horizontal gene transfer, and 
increasing human connections around the world. These factors amplify the 
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phenomenon and increase the global spread of resistant strains, leading to 
dangerous epidemics for which there is no effective treatment, thus increasing the 
awareness of the problem. [19] 
Development of synthetic molecules does not solve the problem either as 
their wide and prolonged use leads anyway to the development of resistance even 
if less quickly at the beginning. This discourages investment in research, 
development and marketing of new drugs. 
Resistant bacteria grow in the presence of antimicrobial substances at 
concentrations that usually kill or inhibit their growth. Drugs become ineffective 
and this leads to reduced options for treatment and to longer and more severe illness 
and an increase in mortality rates. In this way, previously controllable common 
infections and diseases, again become potential killers, especially in hospitals. 
Units such as Intensive care (ICU), hematology, neonatology, or transplantation 
care are exposed to greater risk and have a two-fold mortality rate. [Tab. 1] [22] [23]  
The problem is clinical, with high rates of morbidity and mortality that can 
reach 50-80%, but it also has a high economic impact due to the high costs of 
prolonged hospitalization, prolonged treatments, the use of more expensive drugs, 
increase in the need for screening tests and the need for greater investment in new 
treatments, diagnosis and prevention.  
 
 
Tab. 1 Mortality attributable to antibiotic-resistant bacteria (From WHO) [24] 
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2.2 The size of the problem 
At this point, it is clear that antibiotic resistance is a widespread 
phenomenon. In 2013, the Centers for Disease Control and Prevention (CDC) 
declared that the human race is now in the “post-antibiotic era”. [7] In 2014, World 
Health Organization (WHO) recognized that antimicrobial resistance is a global 
public health crisis, and published a “Global report” to show the situation of 
antimicrobial resistance in the world, related to tuberculosis, HIV, malaria, 
influenza and nine selected bacteria. [Tab. 2] [24]  
 
 
The real extent of the problem, however, is not known, because not all 
countries carry out active surveillance on antibiotic-resistant bacteria and routinely 
surveillance is only for severe infections. Even then data collection is very limited. 
Of 194 countries, 129 (66%) returned information to WHO for this survey, with the 
largest gaps in Africa, the Middle East and European countries outside the European 
Union. [22] [24] [Tab. 3]  
Tab. 2 Combination bacteria/antibiotics focused on WHO Global report 2014 [24] 
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As for morbidity, disability adjusted life years, mortality, length of hospital 
stay, cost of care, related to antibiotic-resistant infections, there are only estimates 
for Europe, USA and the rest of the World published by European Centre for 
Disease Prevention and Control (ECDC), CDC and WHO. [Fig. 11] [7] [ 22] [25] [26]  
CDC estimate that each year in the USA, about 2 million people acquire 
infections with antibiotic-resistant bacteria, and 23,000 people die as direct result 
of these infections. Many others die from conditions complicated by antibiotic 
resistant infection. [7] ECDC reports that each year, about 25,000 patients die in 
Europe, from an infection with multidrug-resistant bacteria and these infections 
count for an extra 2.5 million hospital days. [9] 
To obtain information about the costs associated with antibiotic resistant 
versus antibiotic sensitive pathogens, is very difficult and few economic studies 
have been carried out. [22] The economic burden of antibiotic resistance was 
estimated to be at least 55 billion dollars in the USA in 2000 [23] [27] and EUR1.5 
billion in Europe in 2007. [25] For the USA, productivity losses are estimated to be 
64% of the total estimated 55 billion dollars, whereas for Europe, the estimate is 
40% of the total estimated EUR1.5 billion. [7]  
 
Tab.  3 Countries that provide information to WHO on availability of national data on resistance for nine 
bacteria/antibacterial drug resistance combinations (From Global Report 2014 WHO) [24] 
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The Italian National Health Institute (ISS) published a report on antibiotic 
resistance surveillance from 2005 to 2008, which shows a stable trend for Gram-
positive and an increasing trend for Gram-negative bacteria, especially for 
fluoroquinolones, aminopenicillins and aminoglycosides in E. coli e K. 
pneumoniae/oxytoca, with differences between North and South. [28] [29] 
The ECDC report confirms Italy has one of the highest resistance rates in 
Europe, with an increasing trend in the last years especially for Gram-negative 
bacteria and high percentages of invasive infections. [25] [26] [28] [29] [Tab. 4] [Tab. 5]  
Fig. 11 Estimates of deaths, hospital days and cost for European Union, Thailand and the 
USA. (From WHO) [24] 
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Tab. 5 Details about invasive infections caused from antibiotic resistant bacteria (Data ECDC) [25] 
Tab. 4 Antibiotic resistance trend in Italy from 2003 to 2013 (Data ECDC) [26] 
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Also in Verona hospital, the number of multi-resistant strains is increasing. 
During the period 2009-2015 we observed a general increase of resistant strains 
isolated. For example, carbapenem-resistant K. pneumoniae strains isolated in our 
hospital, were 1.94% in 2009, and arose 61.76% in 2011, dropped to 39.2% in 2015, 
after the beginning of the screening program in 2013 [Graph. 1] 
 
 
 
 
2.3 Action plan 
All national and international agencies recognize antibiotic resistance as a 
complex problem that concerns all nations and requires immediate global measures.  
In the last few years many resolutions and recommendations have been 
proposed and numerous reports have been written. All agree on the need for prudent 
use of antibiotics, prevention of infections and development of new drugs, and 
everybody recognize the crucial role of health care workers in preserving the 
efficacy of antibiotics. 
In May 2015, the World Health Assembly adopted a resolution to develop 
a global action plan [30] to ensure prevention and treatment of infectious diseases 
using safe and effective drugs. The resolution further recommended that national 
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Graph.1 Meropenem-resistant K. pneumoniae strains isolated in Verona hospital between 
2009 and 2015 
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and international organizations should take measures to contain the spread of 
antibiotic-resistant bacteria. 
 
The aims of the global plan are: 
1. To improve awareness and understanding of antimicrobial resistance. 
2. To strengthen surveillance and research. 
3. To reduce the incidence of infection. 
4. To optimize the use of antimicrobial medicines. 
5. To ensure sustainable investment in countering antimicrobial resistance [30] 
 
In collaboration with other International Organizations (FAO, OIE), the 
WHO promote the enhancement of national action plans based on this global plan. 
The aim being to control antibiotic-resistance with a coordinated approach for an 
appropriate use of antibiotics in human health, animal health, food and agriculture. 
It also called for the implementation of a surveillance net and the promotion of 
economic investment in research for development of diagnostic tools and new 
antibiotic compounds. [22] In Europe ECDC and national government promote 
meeting, Technical Advisory Committee (TAC) for the European Antibiotic 
Awareness Day, report and recommendations. [11] [31] [32] [Fig. 12] 
 
Fig. 12 Action to contain antibiotic resistance. [32] 
 25 
 
3. The threat of carbapenem-resistant Enterobacteriaceae  
In the last two decades, the emergence and spread of carbapenem-resistant 
Enterobacteriaceae (CRE) have become a signiﬁcant clinical and public health 
concern. 
The CDC assessed hazard levels in infections caused by antibiotic resistant 
bacteria based on: incidence; 10-year projection of incidence; clinical impact; 
availability of effective antibiotics; transmissibility; economic impact and barriers 
to prevention, classifying the biggest threats for the United States as “urgent,” 
“serious,” or “concerning”.  [Fig. 13] [33]     
 
 
        
 
  
At hazard level “urgent” together with Clostridium difficile, and 
cephalosporin-resistant Neisseria gonorrhoeae there are carbapenem-resistant 
Fig. 13 Hazard level of infections caused by antibiotic-resistant bacteria. (From CDC) [33] 
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Enterobacteriaceae, whereas extended spectrum β-lactamase (ESBL) producer 
Enterobacteriaceae are at level “serious”. 
 Enterobacteriaceae are Gram-negative bacteria colonizers of the 
gastrointestinal tract, present also in animals and in the environment. They are also 
common agents of community-acquired and hospital-acquired infections. E. coli 
for example, is the most frequent urinary tract infection agent, and is also frequently 
involved in peritonitis, bloodstream infections, neonatal meningitis and food-borne 
infections. K. pneumoniae is causative agent of lower respiratory tract infections, 
pneumonia, cystitis, pyelonephritis, device associated-infections and bloodstream 
infections. It is also a major cause of hospital-acquired infections especially in 
neonatology and in intensive-care units, where there are the most vulnerable 
patients and the spread is facilitated by the extensive use of antibiotics and extensive 
use of invasive procedures. [26]   
The usual treatment for infections caused by Enterobacteria are 
fluoroquinolones and cephalosporins especially for urinary tract infections. [5] The 
extensive use of these antibiotics leads to a high level of resistance and 
consequently, increased use of carbapenems, with emerging resistance also for 
these antibiotics.  
The strains resistant to carbapenems, are often resistant to nearly all 
antibiotics and the therapeutic options are limited to combination therapy or older 
antimicrobial agents such as polymyxins and fosfomycin, although resistance to 
colistin has also begun to be reported. [26]                                      
The big clinical impact, of carbapenem-resistant infections, with prolonged 
hospitalization, frequent outbreaks in hospital, high mortality rate [22] [34] [35] and the 
easiness of transmission, makes us understand why they are classified as an urgent 
public health threat, not only in the USA, but also globally.             
Antibiotic resistance in Enterobacteria, especially K. pneumoniae is a public 
health problem of increasing importance also in Europe. The ECDC report shows 
that in the years 2010-2014, as K. pneumoniae and E. coli bacteria resistant to third-
generation cephalosporins, ESBL-producing, as strains resistant to cephalosporins, 
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fluoroquinolones and aminoglycosides have increased significantly in Europe, [26] 
from 17.7% in 2012 to 18.6% in 2015 for K. pneumoniae and from 4.9% in 2012 
to 5.3% in 2015 for E. coli. [36] Also, carbapenem resistance has increased in K. 
pneumoniae whilst it is still rare and stable in E. coli, with percentages of <0.1 % 
reported by the majority of countries. [26] [36] 
There is a large difference in percentage of resistance in European countries, 
for both E. coli and K. pneumoniae, with values higher in both southern and eastern 
Europe. [Fig. 14-16]  
 
 
 
Romania, Italy and Greece have the highest percentages of carbapenem-
resistant K. pneumoniae (31.5%, 32.9% and 62.3% respectively) [Fig. 17] often 
combined with colistin resistance and resistance to all drugs in use. [26] In Italy the 
carbapenem resistance has increased from 1.3% in 2006-2008 to 15% in 2010 and 
32.9% in 2014. [29] 
Fig. 14 Percentages of resistance to III generation cephalosporins for invasive isolates of E. coli in 2012 
and 2015 in European Union (EU)/European Economic Area (EEA). (From ECDC) [36]     
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Fig. 15 Percentages of combined resistance to III generation cephalosporins, fluoroquinolones and 
aminoglycosides for invasive isolates of E. coli in 2012 and 2015 in EU/EEA. (From ECDC) [36] 
Fig. 16 Percentages of combined resistance to III generation cephalosporins, fluoroquinolones and 
aminoglycosides for invasive isolates of K. pneumoniae in 2012 and 2015 in EU/EEA. (From ECDC) 
[36] 
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These data are cause for great concern, because this resistance is due to the 
production of hydrolyzing enzymes encoded by genes located on plasmids and 
therefore easily transferable.  
Rapid diagnosis with measures to contain diffusion have become the most 
important strategies. 
 
 
 
 
 
 
 
 
 
Fig. 17 Percentages of resistance to carbapenems for invasive isolates of K. pneumoniae in 2012 and 
2015 in EU/EEA. (From ECDC) [36] 
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4. Mechanisms of resistance  
The biochemical basis of resistance mechanisms evolved by bacteria are: 
1. Modification of the antibiotic target 
2. Alteration of the cell membrane permeability 
3. Overexpression of efflux-pumps 
4. Degradation of antibiotic by enzymes 
5. Overproduction of the target and bypass of the inhibited metabolic pathway [Fig. 
18]  
 
            
 
Fig. 18 Mechanisms of resistance to antibiotics evolved by bacteria. 1) Modification of antibiotic target; 2) 
Modification of membrane permeability; 3) Overexpression of efflux-pumps; 4) Antibiotic inactivation by hydrolytic 
enzymes; 5) Overproduction of antibiotic target; 6) Alternative metabolic pathway. (Modified from Coates et al. 2002) 
[12] 
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All mechanisms of resistance are an evolution of bacteria to survive 
antibiotic action. There are three ways for this evolution: point mutation can occur 
in a gene encoding for a hydrolyzing enzyme or an antibiotic target. 
Rearrangements of bacterial genome by integrons, transposons or insertion 
sequences that result in activation of new resistance genes can occur. Finally, 
Horizontal Genes Transfer can occur, that is the acquisition of external resistance 
genes plasmid-mediated, bacteriophages-mediated or by naked DNA sequences. 
The resistance to carbapenems by hydrolyzing enzymes is an important example of 
plasmid-mediated resistance. [5] 
Plasmids are the main way for resistance-genes to spread. They are small 
extrachromosomal genetic elements that can auto-replicate and move to another 
cell belonging to the same species or to different species and genera. They carry 
much information including resistance-genes, virulence factors or metabolic 
characteristics. Often plasmids can allocate transposons or other genetic elements 
transposable. Transposons are also important elements for resistance spreading. [5] 
Several resistance genes can be linked on the same plasmids and transfer 
simultaneously with consequent multidrug-resistance. 
Resistance through modification of the antibiotic target can occur through 
the alteration of enzymes targeted by β-lactams, the PBPs, thus developing a lower 
affinity for antibiotics as in S. aureus methicillin-resistant. A modification in 
peptidoglycan reduces affinity for glycopeptides, and an alteration of DNA gyrase 
causes resistance to fluoroquinolones. Finally, alterations of ribosomal binding sites 
result in resistance to tetracyclines, macrolides, lincosamides, streptogramins, and 
aminoglycosides. [5] 
Resistance to β-lactams, aminoglycosides and carbapenems through 
alteration of the cell membrane permeability occurs in Gram-negative bacteria 
when they lose porins. These are proteins that form channels that allow hydrophilic 
molecules of antibiotics, for example β-lactams, to cross the outer membrane. [5] 
Overexpression of efflux-pumps is a mechanism that reduces the 
intracellular accumulation of antibiotics. It is involved in the resistance to 
tetracyclines in Gram-negative bacteria, to β-lactams in P. aeruginosa and to 
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macrolides and streptogramins in streptococci and staphylococci. Moreover, efflux-
pumps cause resistance to fluoroquinolones in staphylococci and enteric bacteria. 
There are four families of these pumps that use H+ antiporters as energy source: 
major facilitator superfamily (MFS); resistance nodulation and cell division (RND); 
staphylococcal multi-resistance (SMR); multidrug and toxic compound extrusion 
(MATE). ATP-binding cassette (ABC), that bacteria use to eliminate toxic 
substances and survive in an unfavorable environment, such as enteric tract, use 
ATP as energy source for active transport. [5] 
Antibiotic degradation by enzymes is the most common mechanism 
confering resistance to β-lactams. These enzymes called β-lactamases, are excreted 
extracellularly by Gram-positive or in the periplasmic space by Gram-negative 
bacteria and break the β-lactam ring of antibiotics. They are encoded by bla genes, 
either chromosomal or located on mobile genetic elements, such as plasmids, often 
linked to other resistance genes in integrons.  
β-lactamases are numerous, differentiated by chemical structure and 
spectrum of activity. For example, penicillinases and cephalosporinases hydrolyze 
a limited number of antibiotics; extended-spectrum β-lactamases (ESBL), 
inactivate nearly all β-lactams including third-generation cephalosporins; 
carbapenemases can inactivate all or nearly all β-lactams. [5] ESBL (TEM, SHV, 
CTX-M, OXA groups) especially created concern in the ‘90s, when they became 
very common in Enterobacteria, primarily E. coli and K. pneumoniae. [37] TEM and 
SHV are inhibited by clavulanic acid, and CTX-M more so by tazobactam, which 
are used in combination with antibiotics (for example amoxicillin-clavulanic acid, 
piperacillin-tazobactam). CTX-M are the most prevalent in all countries. [5] [38] 
Ambler classified β-lactamases in four classes: A, B, C, D. The classes A, 
C and D have an active site with a serine residue; class B have a zinc ion at the 
active site and are called metallo-β-lactamases. [Tab. 6] 
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The resistance phenotypes corresponding to ESBL-producing strains can be 
various, often the resistance is low and consequently, detection can be difficult. 
The use of carbapenems to fight ESBL-producing bacteria lead to the 
appearance of carbapenemase-producing strains that are the major concern 
currently. They belong to class A (KPC) and class B β-lactamases (NDM, VIM, 
IMP). 
Beside β-lactamases, there are other enzymes inactivating antibiotics, such 
as O-adenylyl transferases that modify aminoglycosides or N-acetyltransferases 
that modify chloramphenicol reducing their affinity for target. [5] 
Overproduction of the target and bypass of the inhibited metabolic pathway 
are the mechanisms that confer resistance to sulphonamides and Trimethoprim. [5]    
 
 
 
 
 
 
Tab. 6 Classification of β-lactamases by Ambler (From Mandell) [5] 
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5. Carbapenemases 
Amongst the mechanisms of resistance in Gram-negative bacteria, 
carbapenemases production is very concerning. Their emergence replaced that of 
ESBL, the main concern during late ‘90s. [37] Immediately carbapenemases showed 
themselves to be even more dangerous for different reasons. Indeed, they hydrolyze 
all β-lactams including carbapenems, that are otherwise the last resort in many 
infections; also, carbapenemase genes are transferable so their resistance emerges 
and spreads rapidly; finally, these genes are often associated with other resistance 
genes leading to multidrug-resistance. 
Carbapenemases are numerous, encoded by chromosomal or plasmidic genes. 
The most relevant are KPC, a serine-β-lactamase of class A; NDM, VIM, IMP that 
are metallo-β-lactamase of class B, and OXA-48 belonging to oxacillinases of class 
D, others are for example, IMI, GES, SME, SPM, GIM, other OXA group. [39] 
Several carbapenemases can coexist in the same bacterial strain.  
The carbapenemase-producing strains are mainly K. pneumoniae and E. coli, 
but also other Enterobacteriaceae such as Enterobacter sp., Citrobacter sp., 
Proteus sp. Also, other bacteria families, such as Pseudomonadaceae have been 
reported producing these enzymes. 
 
 
5.1 KPC  
The first KPC-producing strain (K. pneumoniae-carbapenemase) was 
isolated in North Carolina (USA) in 1996, [40] from here it quickly diffused to the 
New York area [41] and to the whole of the United States, [42] afterwards to Israel [43] 
and the rest of the world. [44] [Fig. 19] At the moment, KPC is endemic in many 
countries outside the USA, including Italy [26] where the first case was reported in 
2008, [45] Greece and China. [46]  
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At the moment, 22 variants of this enzyme are known. [48] [49] Among these, 
we first isolated the variant 19 in 2014 in three K. pneumoniae strains. [50] 
The most widespread and characterized ones are KPC-2 and KPC-3 that 
confer very high resistance. Indeed, strains harboring these genes are susceptible 
only to gentamicin, colistin and tigecycline. Therefore, bloodstream infections 
caused by KPC-producing strains have high mortality rate. [47] [51] 
KPC genes are often associated to transposon Tn4401, [52] [53] [Fig. 20] a 
Tn3-type transposon capable of inserting itself into plasmids of Gram-negative 
bacteria that belongs to several incompatibility groups. [54] [55] The plasmid most 
involved in KPC-3 spreading is pKpQIL of incompatibility group IncFII-like. [53] 
[56] [Fig. 20] The same plasmid can carry simultaneously more resistance genes, 
resulting in multidrug-resistance. 
  
Fig. 19 First isolation and distribution of KPC by countries. [47] 
Fig. 20 Complete sequence of pKpQIL plasmid with transoposon Tn4401 containing KPC gene. (On 
the left) [53] Representation of gene blaKPC on transposon Tn4401 and gene blaNDM and blaOXA48. (On 
the right) [48]  
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In the USA and in Europe, Italy included, carbapenemase-producing K. 
pneumoniae are often clonally related to a specific sequence type (ST), ST258 [52] 
harboring pKpQIL plasmid. [57] In Italy, the clone ST512 is also common. [58] In 
Asia, instead, the predominant K. pneumoniae clone is ST11 [48] The wide success 
of clone ST258 is probably due to virulence genes associated with KPC gene in 
these strains. [48] 
 
 
5.2 VIM, NDM, OXA-48 
VIM (Verona integron–encoded metallo-β-lactamase) is a metallo-β-
lactamase first isolated in P. aeruginosa in Verona in 1997, [59] but its’ spreading in 
Europe started in Greece in 2001. [60] [Fig. 21] VIM-producing Enterobacteria have 
been isolated also in South Africa, Nigeria, Tunisia and Mexico, but they are less 
common than KPC. [51] 
 
                                                                                  
 
 Fig. 21 VIM carbapenemase distribution in Europe (2014-2015). [ 61] 
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VIM-encoding gene is located on a mobile cassette in a class 1 chromosomal 
integron, harbored in Pseudomonas sp., but also in Enterobacteriaceae, such as K. 
pneumoniae, K. oxytoca, E. coli, E. cloacae, Proteus mirabilis, and it confers a wide 
resistance at all β-lactams except for aztreonam. [59] Clavulanate, sulbactam and 
tazobactam do not inhibit this enzyme, instead it is inhibited by EDTA, a chelator 
agent, that cannot have clinical use. Up to now 41 VIM variants in 
Enterobacteriaceae have been detected. [49] 
 The NDM (New Delhi metallo-β-lactamase) carbapenemase was first 
isolated in 2008 in an Indian patient returning to Sweden from New Delhi. [62] At 
the moment, it represents the new concern because K. pneumoniae and E. coli 
strains producing this enzyme rapidly spread worldwide carrying a very high level 
of resistance. [48] [Fig. 22] NDM is the most widespread class B carbapenemase. It 
is endemic in India, where it is the most common carbapenemase, in Pakistan, 
Bangladesh and the Balkan states, [46] [48] but it was isolated also in many countries 
worldwide, Italy included. [63] 
          
 
 
Fig. 22 First isolation and spreading of NDM carbapenemase. [46] 
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NDM genes [Fig. 20] are allocated on various plasmids, such as IncF, IncR, 
IncL/M, IncN and IncA/C, that is the predominant, and can spread not only between 
strains of the same species but also between strains of different species. [64] Often, 
other resistance genes, such as ESBL genes or genes encoding resistance to 
aminoglycosides and fluoroquinolones are associated with the NDM gene and K. 
pneumoniae strains carrying them. They belong to various sequence types, such as 
ST11, ST15, ST16, ST147, ST512, ST972. [48] At the moment we know of 15 NDM 
variants. [49] 
OXA-48 is an oxacillinase that confers resistance to penicillin and reduced 
susceptibility to carbapenems, but not to third-generation-cephalosporins. First 
isolated in K. pneumoniae in Turkey in 2003 [65] it later spread to Western and 
Mediterranean Europe (with high prevalence in Spain and France) [46], Northern 
Africa, the Middle East, India, China, South America. [51] [Fig. 23] 
The incidence of OXA-48 producers could be actually, even more elevated, 
but often they are misdiagnosed because this carbapenemase confers low level 
resistance. [51] 
                   
 
Fig. 23 OXA 48 carbapenemase spreading worldwide. [66] 
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Different Enterobacteria can harboring OXA-48 gene [Fig. 20], located 
mainly on highly transferable plasmid of IncL group, associated with an insertion 
sequence (IS1999). [65] The K. pneumoniae clones ST11 and ST101 are often 
associated with this gene. [48] At the moment, 10 variants of this carbapenemase 
have been detected. [49] 
 
 
6. Carbapenemase producers detection  
The necessity to deal with multidrug-resistance requires multiple and 
immediate intervention measures, first of all a rapid detection of resistant strains, 
especially carbapenem-resistant Enterobacteriaceae due to their easy and rapid 
spread and clinical burden. 
The role of the laboratory is very important, because in endemic areas there 
is the need to quickly identify those patients infected by carbapenemase producers 
in order to provide a proper therapeutic regimen, but also to assess a program for 
screening and notification of the carriers in a hospital, to prevent nosocomial 
outbreaks with isolation and contact precautions. For this reason, there is a great 
need to introduce in all clinical laboratories opportune methods of resistant strains 
detection. 
Right now, there are different diagnostic tools available, but not all of them 
are reliable actually, due to costs, time consumption, high numbers of sample 
processing required, as well as laboratory organization. Therefore, some of these 
tools are implemented only in reference laboratory.  
Traditional diagnostics is based on bacterial culture. It uses mostly 
phenotypic methods because they are easy to perform and are cost contained, but 
they are time-consuming and not as specific as molecular tests. Phenotypic tests in 
fact, cannot indicate which enzyme is involved or which other mechanism leads to 
a resistance, and also, they can miss low level resistance, as in the case of OXA-48 
producers. 
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The new molecular or proteomics diagnostics, instead, can be more rapid 
and give more information. However, it is often more expensive and not necessarily 
easy to perform. Another advantage of phenotypic methods versus molecular 
methods is also the possibility to detect new mechanisms of resistance. 
Infection diagnosis can be performed on any clinically significant sample. 
The screening of carriers is usually performed on rectal swab of patients at risk as 
for the case of patients admitted to ICU, candidates for transplants, patients from 
highly endemic countries or from healthcare settings with high prevalence of 
resistance. A colonized patient in the unit bring to screen all other patient to check 
and avoid cross-contamination. 
In clinical microbiology labs, detection of carbapenemase producers usually 
takes about 48-72 hours. The first step is overnight culture of the sample, afterwards 
identification is provided, then susceptibility testing to antibiotics with automated 
or disc diffusion methods is performed and this requires another 18-24 hours. 
Reduced inhibition diameters for ertapenem, imipenem and meropenem in disk 
diffusion assay or Minimum Inhibitory Concentration (MIC) values above the 
breakpoint can direct towards research for carbapenemase production. Ertapenem 
is the carbapenem most used for screening, but it is the least specific because other 
resistance mechanisms also, such as the loss of porins, can affect its MIC value. In 
2013, EUCAST (European Committee on Antimicrobial Susceptibility Testing) 
subcommittee for detection of resistance mechanisms published practical 
guidelines for clinical laboratories, providing the breakpoints for detection of 
carbapenemase-producing Enterobacteriaceae in infected patients. [Tab. 7] [67] 
 
         
Tab. 7 EUCAST clinical breakpoints and screening cut-off for carbapenemase-
producing Enterobacteriaceae detection [67] 
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The confirmation of carbapenemase production require further tests, some 
of them, as Modified Hodge Test or E-test, require another 18-24 hours. However, 
not only are the results ready only after 24 hours, but Modified Hodge Test has also 
low sensitivity, principally for NDM producers, as well as low specificity and is 
therefore not recommended by EUCAST. [67] The MBL E-test can be performed 
with strips of imipenem and imipenem/EDTA (bioMérieux), for the detection of 
metallo-β-lactamase producers, but it is little sensitive if MBL producers have low 
resistance.  
It is important, therefore to have access to rapid and sensitive assays and be 
able to detect and confirm carbapenemase production, also for strains that can 
possibly produce new carbapenemase, thus providing clinicians with rapid adequate 
results. 
The use of selective chromogenic agar plates, such as ChromID Carba agar 
(bioMérieux) or ChromID ESBL agar (bioMérieux) combined with a carbapenem 
disk and the rapid colorimetric assays such Carba NP test, [68] can reduce the turn-
around time to less than 48 hours. Carba NP test, indeed is a rapid phenotypic 
method to identify carbapenemase-producing Enterobacteria strains, it is 
inexpensive and easy to perform. It is based on hydrolysis of carbapenem (usually 
imipenem) that causes acidification of the medium detected by phenol red, as pH 
indicator, which changes from red to yellow. It can be performed directly from a 
colony that is mixed with lysis solution and phenol red solution with antibiotic, and 
provides a result within 2 hours maximum. 
Molecular techniques based on PCR technology, can be performed in 
reference laboratories. Numerous tests have been developed, like simplex and 
multiplex PCR, real-time PCR, microarray, and they are the reference standards for 
identiﬁcation of the genes encoding for carbapenemases. They are more rapid than 
culture-based tests, can give results within 4–6 h; they have high sensitivity and 
speciﬁcity and provide information not only about carbapenemase production, but 
also about what type of carbapenemase is involved, and also if carbapenemase 
genes are chromosomal or plasmidic. Techniques such as Multi-Locus Sequence 
Typing (MLST) and Pulsed-Field Gel Electrophoresis (PFGE) give information 
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about the emergence and spread of bacterial clones. However, all genotypic 
techniques are expensive, very time-consuming and require expertise.  
In the last few years, Mass-Spectrometry (MS) based methods MALDI-
TOF (Matrix Assisted Laser Desorption Ionization Time-of-Flight) [Fig. 24] 
substituted the traditional methods for bacterial identification in many laboratories, 
because it is very fast and it has high sensitivity, specificity and low-costs. [69] [70] 
Numerous studies are being performed to demonstrate the possible use of MALDI-
TOF MS also to distinguish resistant from susceptible strains, based on hydrolysis 
activity of ampicillin, cephalosporins or carbapenems. Indeed, the spectra produced 
from analysis of strains before and after incubation with antibiotic are different if 
the strains hydrolyze the drug, with peaks corresponding to antibiotic before 
incubation and subsequent loss of it or else appearance of a new one which 
correspond to degradation products. [71] [72] This method is more rapid than the 
traditional susceptibility test and provide results in 2-4 hours, but it needs further 
evaluation to optimize the performance and standardize it. Moreover, at the moment 
there is no available software able to analyze the spectra obtained from this kind of 
analysis.  
Another approach for quick identification of resistant strains by MALDI-
TOF MS, is to analyze the spectra trying to detect a pattern in 
characteristic peaks related to resistance determinants. The 
published studies about carbapenemase detection, demonstrate 
the correspondence between KPC production and a peak of 
11,109Da in MALDI-TOF MS spectra. 
[73] [74] [75] This method is faster than 
hydrolysis, is able to provide a result in 
a few minutes, does not require any 
further step other than routine 
identification analysis, does not add costs and is 
also very easy to perform. Finally, many studies 
are being performed to validate the use of MALDI-
TOF MS system for typing bacterial strains. [76] [77]           
Fig. 24 MALDI-TOF Vitek MS RUO 
(bioMérieux). 
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AIM OF THE STUDY 
 
The aim of this study was to evaluate the use of MALDI-TOF MS system 
to identify antimicrobial resistance mechanisms, and in particular to quickly 
identify carbapenemase-producing strains. 
The study was subdivided in three parts with specific objectives: 
 
1. To confirm the correlation between KPC and a characteristic MALDI-TOF MS 
spectrum peak, and demonstrate the usefulness of MALDI-TOF MS system to 
quickly identify KPC-producing Enterobacteria in diagnostics, by the same 
characteristic peak. 
 
2. To find new peaks correlated with other carbapenemases: VIM and NDM. 
 
3. To evaluate the use of MALDI-TOF MS system to quickly detect hospital 
outbreaks. 
 
Moreover, the MALDI-TOF MS results were correlated with phenotypic 
and genetic data to get an epidemiologic and molecular analysis of the diffusion 
pattern of multidrug-resistant Enterobacteria in Verona area. 
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MATHERIAL AND METHODS 
 
1. Bacterial strains 
 
PART I – To validate the use of MALDI-TOF MS system for KPC producers 
detection. 
 
Group 1. To confirm the correlation between KPC and a characteristic 
MALDI-TOF MS spectrum peak. 
A total of 436 Enterobacteriaceae strains (namely 176 KPC-producing; 54 
producing carbapenemases other than KPC; 175 ESBL-producing; 4 carbapenem-
resistant not producing carbapenemases and 27 susceptible to β-lactams) were 
examined to confirm the correlation between KPC production and MALDI-TOF 
MS 11,109Da peak. [73] The strains were selected from clinical isolated, based on 
susceptibility testing results.  
Out of 436 total strains, 128 strains were isolated from rectal and pharyngeal 
swabs from multidrug-resistant (MDR) screening done at the Microbiology 
Laboratory of Verona Hospital, between April 2013 and January 2014 and stored 
in glycerol stock vials at -80°C. Identification and antibiotic susceptibility tests 
were performed beforehand during clinical routine workflow by MALDI-TOF MS 
system (bioMérieux) and automated system Vitek 2 (bioMérieux). 
The strains were namely: 95 KPC-producing K. pneumoniae; 4 KPC-
producing E. coli; 24 ESBL-producing K. pneumoniae; 4 E. coli with reduced 
susceptibility to ertapenem due to non-carbapenemase-based mechanisms; 1 VIM-
producing E. coli. 
One hundred and seven strains were isolated in Microbiology Laboratory of 
“Sacro Cuore” Hospital in Negrar (Verona) from various clinical samples (rectal 
swabs, urine, respiratory specimens, blood-culture, biological fluids) from August 
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2014 to March 2015 and stored in glycerol stock vials at -80°C. They had already 
been identified and tested for antibiotic susceptibility with automated system 
MicroScan Walk Away 96 Plus (Siemens Healthcare Diagnostics). As confirmatory 
test for KPC production Modified Hodge Test was used. 
The strains were namely: 68 KPC-producing K. pneumoniae; 9 KPC-
producing E. coli; 30 ESBL-producing K. pneumoniae.  
During the study, we performed for all these strains identification with 
MALDI-TOF MS system, rapid Carba NP test, [68] MIC evaluation and for 
carbapenemase-producing strains multiplex and simplex PCR for 
blaIMP/blaVIM/blaKPC, blaNDM, blaOXA-48, blaTEM/blaSHV/blaOXA-1, blaCTX-M-1, blaCTX-
M-2, blaCTX-M-9, blaCTX-M 8/25 genes; 
[78] for ESBL-producing strains multiplex PCR 
for blaTEM/blaSHV/blaOXA-1, blaCTX-M-1, blaCTX-M-2, blaCTX-M-9, blaCTX-M 8/25 genes. 
[78] 
Discrepant strains, that is strains carrying blaKPC gene, without the 11,109Da peak, 
were retested twice by MALDI-TOF MS, before and after isolation on Mueller-
Hinton (MH) plates with Imipenem (2 µg/ml), and blaKPC gene sequencing, plasmid 
extraction and characterization [56] [79] and PCRs for p019 and Tn4401 genes was 
performed. 
As control groups we used collection strains, identified and tested for 
antibiotic susceptibility during clinic routine workflow and investigated for bla 
genes. They are namely 27 K. pneumoniae susceptible to all β-lactams; 121 ESBL-
producing E. coli from Verona; 15 Enterobacteriaceae strains from Croatia, 
namely: 8 K. pneumoniae; 2 E. cloacae; 2 C. koseri; 3 transconjugants that have as 
recipient E. coli J53, all NDM-producing; 37 Enterobacteriaceae strains VIM-
producing from Croatia, namely: 2 K. pneumoniae; 25 E. cloacae; 8 C. freundii; 2 
K. oxytoca, and 1 VIM-producing K. oxytoca from Verona. For these strains, we 
performed rapid Carba NP test and the 11,109Da peak detection on MALDI-TOF 
MS spectra. [Fig. 25] 
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Fig. 25 Workflow for selected strains analyzed to confirm correlation between KPC production and 
MALDI-TOF MS 11,109Da peak. 
• Carba NP test 
• MALDI-TOF MS for 11,109Da 
peak detection  
• MIC 
• PCR for bla genes 
 Discrepant strains 
Susceptible to β-lactams; ESBL, 
NDM or VIM producers 
149 from Verona 
52 from Croatia 
436 selected strains 
Control groups from collection 
KPC producers or ESBL 
producers 
128 from Verona 
107 from Negrar 
• Carba NP test 
• MALDI-TOF MS for 11,109Da 
peak detection  
• Re-tested by MALDI-TOF MS 
• Sequencing blaKPC gene 
• Plasmid extraction and characterization 
• PCR for p019 and Tn4401 genes 
 
Group 1 
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Group 2. To demonstrate the usefulness of MALDI-TOF MS system to quickly 
identify KPC-producing Enterobacteria in diagnostics, by 11,109Da 
peak. 
Between May and July 2016, the MALDI-TOF MS spectra of 183 
Enterobacteriaceae strains with rapid Carba NP test [68] or ESBL NDP test [80] 
positive, isolated from rectal and pharyngeal swab during MDR screening at the 
Microbiology Laboratory of Verona Hospital, were analyzed daily to detect the 
11,109Da peak. The strains were namely: 124 K. pneumoniae; 8 E. coli; 2 E. 
aerogenes; 1 E. cloacae, all carbapenemase producers; 47 K. pneumoniae and 1 E. 
coli ESBL producers. All strains were isolated on ChomeID ESBL agar 
(bioMérieux) with Ertapenem (10 µg) disk and identified by MALDI-TOF Vitek 
MS RUO (bioMérieux). The discrepant strains with positive Carba NP test and 
without the 11,109Da peak were re-tested twice by MALDI-TOF MS, before and 
after isolation on MH plates with Imipenem (2 µg/ml), and investigated by 
multiplex and simplex PCR for blaIMP/blaVIM/blaKPC and blaNDM 
[78] genes, then if 
positive for blaKPC gene, we performed sequencing of the gene, plasmid extraction 
and characterization, [56] [79] and PCR for p019 and Tn4401 genes. [Fig.26]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 26 Workflow to evaluate the application of MALDI-TOF MS 11,109Da peak detection in 
diagnostic routine. 
• MALDI-TOF MS for 
11,109Da peak detection  
 
183 strains from routine with Carba 
NP test or ESBL NDP test positive 
• Re-tested by MALDI-TOF MS 
• PCR for bla genes 
• Sequencing blaKPC gene 
• Plasmid extraction and characterization 
• PCR for p019 and Tn4401 genes 
 
Group 2 
 Discrepant strains 
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Group 3. To search NDM-producing E. coli. 
After finding an NDM-producing E. coli strain in the Group 2, we 
performed a retrospective analysis on 11 E. coli strains carbapenem-resistant 
collected from January to November 2015 and stored at -80°C, to search for other 
strains producing the same enzyme. All strains were analyzed by MALDI-TOF MS 
to detect the 11,109Da peak and by multiplex and simplex PCR for 
blaIMP/blaVIM/blaKPC e blaNDM 
[78] genes. The discrepant strains, that is strains 
carrying blaKPC gene, without the 11,109Da peak, were retested by MALDI-TOF 
MS and we performed sequencing blaKPC gene, plasmid extraction and 
characterization, [56] [79] and PCR for p019 and Tn4401 genes. [Fig. 27] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• MALDI-TOF MS for 11,109Da 
peak detection 
• PCR for bla genes 
11 Carbapenemase-producing 
E. coli strains from collection 
 
Fig. 27 Workflow to detect NDM-producing E. coli strains. 
• Re-tested by MALDI-TOF MS 
• Sequencing blaKPC gene 
• Plasmid extraction and characterization 
• PCR for p019 and Tn4401 genes 
 
Group 3 
 Discrepant strains 
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PART II - To find peaks correlated with other carbapenemases: VIM and 
NDM. 
Group 4 
To find a specific peak correlated with VIM and NDM enzyme, we analyzed 
from frozen stock, 57 Enterobacteria strains from Croatia (36 out of 57 were the 
same of group 1) and 61 Pseudomonas aeruginosa strains by collection. After 
confirmation of carbapenemase production with Carba NP test and PCR for 
blaIMP/blaVIM/blaKPC e blaNDM 
[78]
 genes, we selected 23 and 13 strains respectively, 
all VIM-producing, positive for Carba NP test, to create a MALDI-TOF MS 
superspectrum and to search for a specific peak. For 2 strains (1 C. freundii and 1 
K. oxytoca) we performed conjugation with E. coli J53 as recipient, to obtain trans-
conjugant strain VIM-producing. [Fig. 28] 
We created also a superspectrum to search for a NDM specific peak, using 
the 15 NDM-producing strains of Group 1. [Fig. 25] [Fig. 28] After the first spectra 
analysis, we characterized the plasmids of the NDM- and VIM-producing strains, 
and based on the high frequency of appearance, we divided the samples in groups 
then repeating the spectra analysis to check if, in this way, we would find a common 
peak, related to one of the plasmids.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
57 Enterobacteriaceae +   61 P. 
aeruginosa carbapenemase-producing 
strains from collection 
• Carba NP test 
• PCR for bla genes 
23 VIM-producing Enterobacteriaceae  
13 VIM-producing P. aeruginosa 
15 NDM-producing 
Enterobacteriaceae 
Fig. 28 Workflow to create VIM and NDM superspectra for finding characteristic MALDI-
TOF MS peaks correlated with these carbapenemases. 
Group 4 
• MALDI-TOF VIM and NDM superspectra 
• First spectra analysis 
• Plasmid characterization 
• Repeated spectra analysis 
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PART III - To evaluate the use of MALDI-TOF MS system to quickly detect 
hospital outbreaks. 
 
Group 5 
Forty-four K. pneumoniae strains by frozen collection, isolated during an 
outbreak onset in our hospital ICU from January to March 2015 and already 
identified and tested for antibiotic susceptibility during routine clinic workflow. For 
all strains, we confirmed carbapenemase production with Carba NP test and PCR 
for blaIMP/blaVIM/blaKPC genes, 
[78] and we performed MALDI-TOF MS analysis to 
detect the 11,109Da peak and to find genetic correlation, and PFGE. 
The discrepant strains, that is strains which carried blaKPC gene, without the 
11,109Da peak, were retested twice by MALDI-TOF MS, before and after using 
MH plates additioned with Imipenem (2 µg/ml), and we performed sequencing 
blaKPC gene, plasmid extraction and characterization
 [56] [79] and PCR for p019 and 
Tn4401 genes. [Fig. 29] 
 
 
 
 
 
 
 
 
 
 
 
• Carba NP test 
• PCR for bla genes 
• MALDI-TOF MS analysis 
• PFGE 
• Re-tested by MALDI-TOF MS 
• Sequencing blaKPC gene 
• Plasmid extraction and characterization 
• PCR for p019 and Tn4401 genes 
 
Fig. 29 Workflow to evaluate the use of MALDI-TOF MS to detect clonal correlation between bacterial 
strains. 
44 KPC-producing K. 
pneumoniae from ICU outbreak 
 
Group 5 
 Discrepant strains 
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Control strains  
As positive and negative controls for Carba NP test, ESBL NDP test and for 
PCR for bla genes we used well-characterized strains. [Tab. 8] 
 
 
Negative control E. coli ATCC 25922[81] 
KPC positive control K. pneumoniae KL301 [82]
 
VIM positive control P. aeruginosa VR 143/97 [59] 
NDM positive control K. pneumoniae KLZA [83] 
OXA-48 positive control K. pneumoniae KPN2605 
[84] 
TEM/SHV/OXA-1 positive control K. pneumoniae KPN2605 [84] 
ESBL positive control E. coli ATCC BAA2326 [81] 
 
 
 
 
2.  Carbapenemase-producing strains detection 
To isolate carbapenemase-producing strains, the samples were inoculated 
on selective chromogenic ChromID ESBL agar plates (bioMérieux) with 
Ertapenem disk (10 µg) and incubated at 37°C overnight. Isolates that showed 
reduced susceptibility to ertapenem (< 22mm diameter) [85] were further 
investigated by confirmatory test and MALDI-TOF MS identification, after passage 
on Mueller-Hinton home-made agar plates. [Fig. 30] 
  
 
Tab. 8 Negative and positive controls used for Carba NP test, ESBL NDP test and 
PCR for bla genes 
Fig. 30 Green colonies of carbapenemase-
producing K. pneumoniae on selective 
ChromID ESBL agar plate (bioMérieux), 
with ertapenem disk. 
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3. Identification by MALDI-TOF MS system and spectra analysis to detect the 
11,109Da peak 
Mass spectrometry has been used from ‘80s to analyze with high accuracy 
a protein’s molecular weight. [86] Since 1996, this technology has been applied by 
Matrix Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry 
(MALDI-TOF MS) system, that quickly (~1minute) identify bacterial strains at 
genus, species and, sometimes, at subspecies level. Two systems of Mass 
Spectrometry are applied to microbiology: one developed by Bruker Daltonics 
(Germany) and the other by bioMérieux/Shimadzu (France/Japan). The Bruker 
system uses the software MALDI Biotyper, whereas the bioMérieux/Shimadzu 
system uses own software, namely, Shimadzu Launchpad and database 
SARAMISTM Premium (Spectral ARchivee And Microbial Identification System) 
ID-professional (AnagnosTec-bioMérieux). [87] [88] 
The MALDI-TOF MS system analyzes ribosomal proteins of the strains 
spotted in a plastic slide, [Fig. 31] crystallized by a matrix and ionized by a pulsed 
laser 50Hz ultraviolet frequency, which hits each spot 500 times. The sample is 
pulsed in a flight tube and the proteins are separated by an electric field according 
to their molecular weight. The system measures the mass/charge ratio (m/z) and it 
generates a spectrum with peaks corresponding to molecular masses, with quality 
representation of relative intensity. The spectrum is automatically acquired and 
compared with superspectra and reference spectra in the database, to provide 
identification result of bacterial strains. [69] [89] [90] 
This technology is very reliable, rapid and accurate, and it also has low 
costs. It is very important, however, to guarantee the reproducibility of the results, 
to always operate in the same conditions, for example to use the same culture 
conditions, the same plates or extraction method. This is necessary specially to find 
characteristic peaks and to perform comparisons between strains. 
In our study, all strains were identified by MALDI-TOF Vitek MS RUO 
Axima@Saramis (bioMérieux) system, in duplicate, from fresh overnight cultured 
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colony spotted in a plate with 1 µl of α-cyano-4-hydroxycinnamic acid (α-CHCA) 
matrix, [Fig. 31] according to manufacturer indications.  
For all strains except group 2, all MALDI-TOF MS measurements were 
performed by the same operator, for Group 2 strains (routine detected strains) also 
by other operators so as to investigate for potential differences on the results.  
                                  
 
Our MALDI-TOF MS spectra were compared with Saramis database 
(~20,000 bacterial and fungal spectra) for strains identification. According to the 
manufacturer’s criteria, a result was considered valid (accurate identiﬁcation to the 
species level) whenever the confidence was ≥90%. The results are showed with 
different colors according to the confidence of analysis: dark green ≥99% and light 
green ≥90% if the result is very reliable; yellow ≥85% high probable; white ≥70% 
not sure, two or more species proposed; red <70%, not acceptable, possible mixture 
of strains. [Fig. 32]  
 
Fig. 31 Slides and reagents for MALDI-TOF MS measurements. 
measurements. 
Fig. 32 Color code for MALDI-TOF MS results. 
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 The mass measured by MALDI-TOF MS system using CHCA matrix range 
from 2,000 to 20,000Da, the parameter settings to detect the 11,109Da peak were: 
Relative Intensity ≥ 0; Absolute Intensity ≥ 0; Error % 0.08. 
Spectra obtained at an initial stage of identification were also used to detect 
the 11,109Da (± 8Da) peak. They were imported into the database, thus creating a 
folder for each genus and looking for the peak in question. [Fig. 33] 
 
 
 
 
 
 
 
Fig. 33 11,109Da peak detection importing strains spectra in database and comparing mass vs 
spectra. 
11,109 
Compare masses vs spectra 
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4. MALDI-TOF MS superspectra creation 
To find a characteristic peak correlated with carbapenemases other than KPC, 
as NDM and VIM, we used MALDI-TOF MS system to create two specific 
superspectra. That is a set spectra produced by similar strains, therefore with 
common peaks, which can use for rapid comparison. [88] To perform this, we made 
measurements for NDM- and VIM- producing strains and analyzed the spectra by 
Saramis, then imported our spectra, we created a NDM and a VIM superspectrum. 
The peaks of these superspectra were used to create an exclusion list to eliminate 
the proteins most represented and common also to susceptible strains of the 
database, until step by step, we selected only a few proteins that could be correlated 
with carbapenemases, to investigate whether the latter could be common to all 
strains producing the same enzyme. [Fig. 34]  
                             
 
 
 
 
 
Fig. 34 Creation of superspectrum VIM and selection, step by step, of proteins to find a peak 
correlated with the enzyme. 
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5. Antimicrobial Susceptibility Testing 
Antimicrobial susceptibility tests were performed with automated systems 
during clinical routine and by broth microdilution for carbapenems, cephalosporins 
and aztreonam, in this study. The results were interpreted following the EUCAST 
breakpoints. [85] [Tab. 9] 
 
 
The antibiotics tested were carbapenems: ertapenem, meropenem, 
imipenem; cephalosporins: cefotaxime, cefepime, ceftazidime; monobactams: 
aztreonam. We used 96 well microdilution plates. Each well was filled with 100 µl 
of Mueller-Hinton (MH) broth, later adding another 100 µl in the first well. Then, 
for imipenem/cylastatin 10.24 μl from a 10 mg/ml mother solution was pipetted 
into the first well, and for the other antibiotics 5.12 μl, and made serial dilution, to 
obtain final 100 µl in each well. Finally, 100 μl of 
bacterial inoculum in MH broth, with 105 cfu/ml 
was added in each well, obtaining antibiotic 
concentrations of 128 μg/ml in the first well and 
0.06 μg/ml in the last one. The microdilution plates 
were incubated overnight at 37 ºC. [Fig. 35]  
Fig. 35 MIC determination with broth 
microdilution method. 
Tab. 9   EUCAST clinical breakpoints of cephalosporins, carbapenems and monobactams for Enterobacteriaceae 
[85] 
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6. Beta-lactamases detection and characterization 
 
6.1 Colorimetric confirmatory test:  
ESBL NDP test and Carba NP test  
Rapid phenotypic tests: ESBL NDP test [80] and Carba NP test, [68] were 
performed for all samples with reduced susceptibility to cephalosporins or to 
carbapenems, to confirm ESBL or carbapenemases production. 
The test was made on samples and on positive and negative controls [Tab. 
8] using fresh colony (not more than 24 hours) from overnight culture. For each 
sample, including both positive and negative controls, two tubes of 1.5 ml were 
prepared. In all tubes, we distributed 100 µl of Tris-HCl 20 mM lysis buffer (B-
PER II, Bacterial Protein Extraction Reagent, Thermo Scientific Pierce) and the 
colony to be tested, and well mixed. In the first tube of each sample used as test 
control, we added 100 µl of phenol red solution (solution A). In the second tube of 
each sample, that is the test tube, we added 100 µl of solution A with antibiotic, at 
the concentration of 3 mg/mL, prepared just before 
use: imipenem for Carba NP test, [68] ceftazidime for 
ESBL NDP test. [80] Solution A was prepared mixing 
2 ml of concentrated phenol red solution (0.5% w/v) 
and 16.6 ml of distilled water, adjusting the pH at 7.8 
and adding 180 µl of ZnSO4 (Merck) 10 mM to obtain 
a final concentration of 0.1 mM.  
All tubes were incubated at 37°C for max two hours (usually for KPC 
producers, positive result requires between 2 and 30 min; for MBL producers 
between 15 min and 1h; for OXA-48-like producers between 20 and 2h). The test 
was interpreted positive if the color of test tube changed from red to yellow, because 
carbapenemase or ESBL produced by sample, hydrolyze the antibiotic, causing a 
pH change evidenced by phenol red (pH indicator) solution becoming yellow. The 
test was interpreted negative if both tubes were red, and was not interpretable if 
control test tube or both tubes were yellow. [Fig. 36]  
Fig. 36 Rapid Carba NP test home-
made. On the left positive result, on 
the right negative result. 
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    6.2 Molecular detection:  
     PCRs for carbapenemase and ESBL genes detection 
Multiplex and simplex PCRs for carbapenemases genes detection 
(blaIMP/blaVIM/blaKPC, blaNDM and blaOXA48) 
[78] were performed for samples of 
Group 1 carbapenem-resistant and for discrepant samples. PCRs for relevant ESBL 
genes (blaTEM/blaSHV/blaOXA-1, blaCTX-M-1, blaCTX-M-2, blaCTX-M-9, blaCTX-M 8/25) 
[78] 
were performed for ESBL-producing samples of Group 1.  
Bacterial DNA was prepared transferring a small amount of sample colony 
into 1.5 ml tubes with 350 μl of distilled water, boiling at 100°C for 10 minutes and 
followed by centrifugation at 13,000 rpm for 5 minutes.  
We used for each sample 2 μl of supernatant, 20 μl of 5 Prime Hot Master 
Mix-1000R (5 Prime) (Quanta BioScienses Inc.), a variable concentration of 
speciﬁc-group primers and filled up with distilled water for a total volume of 50 μl 
PCR reaction. Positive [Tab. 8] and negative control (without DNA template) were 
included in each amplification process. All primers were synthetized by Eurofins 
Genomics MWG Operon. [Tab. 10] 
The PCR reactions were analyzed by electrophoresis with 0.8% agarose gel 
at 100 V for 60 min in 1x TAE [40 mM Tris–HCl (pH 8.3), 2 mM acetate and 1 
mM EDTA] and stained with 1x Gel Red solution (Biotium). 
Multiplex blaIMP/blaVIM/blaKPC PCR thermal profile was: 30 cycles of 
denaturation at 94°C for 40 sec; annealing at 55°C for 40 sec; extension at 72°C for 
1 min and one final elongation cycle at 72°C for 7 min, obtaining 139bp, 390bp and 
538bp product respectively. [78] [Tab. 10] 
The blaNDM PCR was performed using the thermal profile: 30 cycles at 94°C 
for 1 min; 55°C for 1 min and 72°C for 1 min, and final elongation cycle at 72°C 
for 10 min, obtaining 800bp product. [Tab. 10] 
The blaOXA-48 PCR was performed using: 30 cycles at 94°C for 40 sec; 57°C 
for 40 sec and 72°C for 1 min, and final elongation cycle at 72°C for 5 min resulting 
in 400bp PCR product. [78] [Tab. 10] 
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Gene 
amplified  
Primer name  Primer sequence       5’             3’ Amplicon 
Size (bp) 
Primer 
concentration 
(pmol/mL) 
blaIMP IMP FW TTG ACA CTC CAT TTA CDG  139 0.5 
 IMP REV GAT YGA GAA TTA AGC CAC YCT   0.5 
blaVIM VIM FW GAT GGT GTT TGG TCG CAT A  390 0.5 
 VIM REV CGA ATG CGC AGC ACC AG   0.5 
blaKPC KPC FW CAT TCA AGG GCT TTC TTG CTG C  538 0.2 
 KPC REV ACG ACG GCA TAG TCA TAT GC   0.2 
blaNDM NDM A CAC CTC ATG TTT GAA TTC GCC  800 0.5 
 NDM B CTC TGT CAC ATC GAA ATC G   0.5 
blaOXA-48 OXA-48 FW TTG GTG GCA TCG ATT ATC GG  400 0.5 
 OXA-48 Rev CAG CAC TTC TTT TGT GAT GCC   0.5 
 
Multiplex blaTEM/blaSHV/blaOXA-1; multiplex blaCTX-M-1/blaCTX-M-2/blaCTX-M-
9 groups; blaCTX-M-8/25 PCR reactions were performed with 30 cycles of denaturation 
at 94°C for 40 sec; annealing at 60°C for 40 sec; elongation at 72°C for 1 min and 
a final elongation at 72°C for 10 min.  [78] [Tab. 11]  
 
 
Gene 
amplified 
Primer name Primer sequence    5’             3’ 
Amplicon 
Size (bp) 
Primer 
concentration 
(pmol/mL) 
blaTEM-1 
blaTEM-2 
TSO-T FW CAT TTC CGT GTC GCC CTT ATT C  800 0.4 
TSO-T REV CGT TCA TCC ATA GTT GCC TGA C   0.4 
blaSHV-1 TSO-S FW AGC CGC TTG AGC AAA ATT AAA C  713 0.4 
TSO-S REV  ATC CCG CAG ATA AAT CAC CAC   0.4 
Tab. 10 Primers used for carbapenemase genes screening [78] 
Tab. 11 Primers used for β-lactamase genes screening [78] 
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7. Amplicon Sequencing   
For discrepant strains, the PCR products were column-purified by 
QIAquick® PCR Purification kit (Qiagen) and sent to Eurofins MWG Operon 
Ebersberg (Germany) for sequencing. Amplicons sequenced were analyzed by 
NCBI Genebank database on BLAST (basic local alignment search tool) program. 
[91] For blaKPC amplicons sequencing, we used additional primers: KPC FW 5’ TGT 
CAC TGT ATC GCC GTC TAG 3’; KPC REV 5’ TTA CTG CCC GTT GAC GCC 
CAA TCC 3’.  
 
blaOXA-1, 
blaOXA-4, 
blaOXA-30 
TSO-O FW  GGC ACC AGA TTC AAC TTT CAA C  564 0.4 
TSO-O REV GAC CCC AAG TTT CCT GTA AGT G   0.4 
blaCTX-M-1, 
blaCTX-M-3, 
blaCTX-M-15 
CTX-M-1 FW TTA GGA ART GTG CCG CTG YA  688 0.4 
CTX-M-1-2 REV CGA TAT CGT TGG TGG TRC CAT   0.2 
blaCTX-M-2 CTX-M-2 FW CGT TAA CGG CAC GAT GAC  404 0.2 
CTX-M-1-2 REV CGA TAT CGT TGG TGG TRC CAT  0.2 
blaCTX-M-9, 
blaCTX-M-14 
CTX-M-9 FW TCA AGC CTG CCG ATC TGG T  561 0.4 
CTX-M-9 REV TGA TTC TCG CCG CTG AAG   0.4 
blaCTX-M-8/25 CTX-M-8/25 FW AAC RCR CAG ACG CTC TAC 326 0.4 
CTXM-8/25 REV TCG AGC CGG AA8 GTG TYA T   0.4 
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8. Plasmid extraction 
Plasmid extraction was performed for discrepant strains with QIAPrep® 
Spin Miniprep Kit (Qiagen, Germany) from an overnight 5ml inoculum in Luria-
Bertani (LB) broth. Before and after digestion with EcoRI and BamHI restriction 
enzymes (Roche), at 37°C for 1h, the plasmids extracted were loaded in a 0.6% 
(w/v) agarose gel and visualized after running at 100V for 60 min. The gel was 
stained with 1x Gel Red solution (Biotium) for 30 min. The presence of blaKPC gene 
was confirmed by single PCR. [Tab. 10] 
 
9. Plasmid characterization 
The characterization of plasmids based on Inc/rep identification was 
performed for discrepant strains and for 8 KPC-producing strains with 11,109 Da 
peak as control group. 
Five multiplex and 3 simplex PCR-based replicon typing (PBRT) [56] and 4 
simplex PCR for IncQ, IncR, IncU, OriColE genes, [79] [92] were performed, using 
the primers summarized in Tab. 12 and 13. 
For each reaction, we used 2 μl of sample, 0.5 μl of each primer, 20 μl of 5 
Prime Hot Master Mix-1000R (5 Prime) (Quanta BioScienses Inc.) and filled with 
distilled water for a total final volume of 50 μl for each reaction. 
The thermal profile of all five multiplex PCRs and simplex PCRs, except 
for F rep and IncQ, was: 30 cycles of 94 ºC for 1 min, 60 ºC for 30 sec, 72 ºC for 1 
min and final elongation at 72 ºC for 5 min. Simplex PCR for F rep the annealing 
was at 52 ºC. [56] For IncQ annealing was at 62°C for 1 min and elongation at 72 ºC 
for 10 min. [79] 
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Replicon 
amplified 
Primer name  Primer sequence       5’                3’      Amplicon 
Size 
HI1 HI1FW GGA GCG ATG GAT TAC TTC AGT AC  471 
 HI1 REV TGC CGT TTC ACC TCG TGA GTA   
HI2 HI2 FW TTT CTC CTG AGT CAC CTG TTA ACA C  644 
 HI2 REV GGC TCA CTA CCG TTG TCA TCC T   
H1 H1 FW CGA AAG CCG GAC GGC AGA A  139 
 H1 REV TCG TCG TTC CGC CAA GTT CGT   
X X FW AAC CTT AGA GGC TAT TTA AGT TGC TGA T  376 
 X REV TGA GAG TCA ATT TTT ATC TCA TGT TTT AGC   
L/M L/M FW GGA TGA AAA CTA TCA GCA TCT GAA G  785 
 L/M REV CTG CAG GGG CGA TTC TTT AGG   
N N FW GTC TAA CGA GCT TAC CGA AG  559 
 N REV GTT TCA ACT CTG CCA AGT TC   
FIA FIA FW CCA TGC TGG TTC TAG AGA AGG TG  462 
 FIA REV GTA TAT CCT TAC TGG CTT CCG CAG   
FIB FIB FW GGA GTT CTG ACA CAC GAT TTT CTG  702 
 FIB REV CTC CCG TCG CTT CAG GGC ATT   
W W FW CCT AAG AAC AAC AAA GCC CCC G  242 
 W REV GGT GCC CGG CAT AGA ACC GT   
Y Y FW AAT TCA AAC AAC ACT GTG CAG CCT G  765 
 Y REV GCG AGA ATG GAC GAT TAC AAA ACT TT   
P P FW CTA TGG CCC TGC AAA CGC GCC AGA AA  534 
 P REV TCA CGC GCC AGG GCG CAG CC   
FIC FIC FW GTG AAC TGG CAG ATG AGG AAG G  262 
 FIC REV TTC TCC TCG TCG CCA AAC TAG AT   
A/C A/C FW GAG AAC CAA AGA CAA AGA CCT GGA  465 
 A/C REV ACG ACA AAC CTG AAT TGC CTC CTT   
T T FW TTG GCC TGT TTG TGC CTA AAC CAT  750 
 T REV CGT TGA TTA CAC TTA GCT TTG GAC   
FIIs FIIs FW CTG TCG TAA GCT GAT GGC  270 
 FIIs REV CTC TGC CAC AAA CTT CAG C   
F FrepB FW TGA TCG TTT AAG GAA TTT TG  270 
 FrepB REV GAA GAT CAG TCA CAC CAT CC   
K K/B FW GCG GTC CGG AAA GCC AGA AAA C  160 
 K REV TCT TTC ACG AGC CCG CCA AA   
B K/B FW GCG GTC CGG AAA GCC AGA AAA C  159 
 B/O REV TCT GCG TTC CGC CAA GTT CGA   
Tab. 12 Primers used for PCR based replicon typing (PBRT) [56] 
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Replicon 
amplified 
Primer name Primer sequence  5’               3’ Amplicon 
size 
IncQ repB IncQ repB 1 FW TCG TGG TCG CGT TCA AGG TAC G 1160 
 IncQ repB 2 REV CTG TAA GTC GAT GAT CTG GGC GTT  
IncR IncR FW TCG CTT CAT TCC TGC TTC AGC 251 
 IncR REV GTG TGC TGT GGT TAT GCC TCA  
IncU IncU FW TCA CGA CAC AAG CGC AAG GG 843 
 IncU REV TCA TGG TAC ATC TGG GCG C  
ColE OriColE FW GTT CGT GCA TAC AGT CCA 187 
 OriColE REV GGC GAA ACC CGA CAG GAC T  
 
10. PCR for p019 and Tn4401 genes detection 
For 8 discrepant strains and 8 KPC-producing strains with the 11,109 Da 
peak in MALDI-TOF MS spectra, used as control group, we performed also 
simplex PCRs to detect p019 and Tn4401 genes, using the primers summarized in 
Tab. 14. [Ref. this study]  
For each reaction, we used 2 μl of sample, 0.5 μl of each primer, 20 μl of 5 
Prime Hot Master Mix-1000R (5 Prime) (Quanta BioScienses Inc.) and filled with 
distilled water for a total final volume of 50 μl for each reaction. The thermal 
profiles were for p019: 30 cycles of 94 ºC for 1 min, 56 ºC for 1 min, 72 ºC for 1 
min and final elongation at 72 ºC for 2 min; for Tn4401: 30 cycles of 94 ºC for 1 
min, 58 ºC for 1 min, 72 ºC for 1 min and final elongation at 72 ºC for 2 min, 
obtaining ~300bp and ~400bp PCR product respectively.  
 
Gene 
amplified  
Primer name  Primer sequence   5’              3’ Amplicon 
Size (bp) 
Primer 
concentration 
(pmol/mL) 
p019 p019 FW GCG GTT GAC AAA ACC ATG ~300 0.5 
 p019 REV GCT CAA ACG TCA CTA TGG C  0.5 
Tn4401 Tn4401 FW AAG TCG AGC ATG AAG CGC A ~400 0.5 
 Tn4401 REV TGA CCA CGG ACG ATG CAA T  0.5 
 
Tab. 13 Primers used for Inc group PCRs [79] [92]  
Tab. 14 Primers used for p019 and Tn4401 genes screening 
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11. Conjugation assay  
Conjugation assay was performed for 2 strains of VIM-producing 
Enterobacteria from frozen collection, namely: 1 C. freundii and 1 K. oxytoca as 
donors and J53 sodium azide resistant E. coli as recipient. [93]  
For each strain, 5 ml of LB broth inoculum were incubated at 37 ºC 
overnight. Afterwards we prepared 3 tubes, one with 500 μl of donor in 5 ml of LB 
broth, one with 500 μl of recipient in 5 ml of LB broth, the last with 500 μl of both 
in 5 ml of LB broth, incubated at 37°C for 6 hours. To select trans-conjugant cells, 
we used LB agar plates supplemented with 100 mg/L sodium-azide and 2 μl/ml 
imipenem. The growth of trans-conjugant cells was verified by MALDI-TOF MS 
identification. [94]  
 
 
12. Strains typing  
 
12.1 Pulsed-field gel electrophoresis (PFGE) 
PFGE was performed for K. pneumoniae strains isolated during an epidemic 
onset in ICU, to determine genetic relatedness. 
We adopted the Han protocol with some modifications. [95] 
For each sample 400 µl of a LB broth inoculum incubated overnight at 37°C, 
was centrifuged at 8000 rpm for 5 min. The pellet was resuspended in 400 µl TE 
buffer (50mM Tris-HCl pH 7.5, 50mM EDTA pH 8). Then it was additioned with 
20 µl of proteinase K (20 mg/ml) and 400µl 2 % (w/v) low-melting agarose 
(SeaKem Gold) and pipetted in wells of a reusable plug mold (Bio-Rad). Solidified 
at room temperature for 10 min and at 4°C for another 10 min, the plugs were 
transferred in 5 ml of lysis buffer (Tris 50mM, EDTA 50mM at pH 8, 0.5 mg 
proteinase K/ml; 1 % sarcosine) and incubated at 54 ºC overnight in a water bath. 
The lysis buffer was removed and the plugs washed two times with 15ml of sterile 
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ultrapure water and four times with 15 ml of TE buffer (Tris 10mM; EDTA 1mM 
pH 8.0). The washing steps were performed at room temperature for 2 hours with 
constant agitation. The plugs were digested with 10 U XbaI enzyme (Thermo 
Scientific) at 37 ºC overnight and placed into the wells of 1% (w/v) PFGE certified 
agarose gel (Bio-Rad) prepared in 0.5x TBE buffer (Tris 44.5 mM, pH 7.5; boric 
acid 44.5 mM; EDTA 1 mM at pH 8). The run was accomplished in CHEF 
MAPPER system (Bio-Rad) in 0.5x TBE buffer with conditions of 6V/cm, 120º 
angle, initial switch time 6.8 sec and final switch time 63.8 sec for 23 hours at 14 
ºC. The gel was stained with 1x GelRed (Biotium) for 30 min. [95] The marker was 
Pulse Marker™ (Sigma-Aldrich) 50-1,000kb. 
The results were analyzed and compared using FPQuest™ Software 
(Version 4.5, Bio-Rad). Similarity analysis was performed by Dice coefficients 
(SD) [96] with position tolerance of 1.5%.     
 
 
 
12.2 MALDI-TOF MS spectra correlation between strains 
With MALDI-TOF MS RUO it is possible to compare different strains to 
investigate clonal correlation, this is useful to compare strains isolated during an 
outbreak. For this purpose, we analyzed the spectra of selected strains, then we 
imported the spectra into the database. The software Saramis analyzed the spectra 
and compared them, producing a dendrogram based on protein profile. Relative 
taxonomy and absolute taxonomy can be shown, illustrating the percentages of 
similarity of masses in different spectra or the coincident mass number. [Fig. 37] 
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Fig. 37   Relative taxonomy: spectra comparison with dendrogram showing 
percentage of similarity (above) and masses comparison (below). 
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RESULTS 
 
PART I 
a. MALDI-TOF MS spectra analysis to evaluate the correlation between 
KPC production and 11,109Da peak 
In the first part of the study, we confirmed the association between KPC 
production in Enterobacteriaceae and the presence of 11,109Da peak [73] in 
MALDI-TOF MS spectra and we evaluated the use of peak detection during clinical 
routine workflow. For this purpose, we selected two samples groups: the first group 
was used to confirm the correlation KPC enzyme production/11,109Da peak; the 
second group was used to confirm the possibility to use the peak search during 
routine diagnostic work to quickly obtain reliable results about KPC production. 
  
Group 1  
 A total of 436 Enterobacteriaceae strains: 128 from Verona and 107 from 
Negrar Hospital, isolated during routine diagnostics and 201 as control group from 
collection, were analyzed.  
 The strains from Verona Hospital were: 100 carbapenem-resistant (95 K. 
pneumoniae and 5 E. coli); 4 ertapenem-resistant E. coli and 24 cephalosporin-
resistant K. pneumoniae. The strains from Negrar Hospital were: 77 carbapenem-
resistant (68 K. pneumoniae and 9 E. coli) and 30 cephalosporin-resistant K. 
pneumoniae. 
 For all these strains, we performed identification and susceptibility testing 
during routine workflow and during the study we confirmed the pattern of 
resistance by MIC evaluation and carbapenemase production by rapid Carba NP 
test. [68] PCRs for bla genes were performed to investigate the mechanism of 
resistance.  
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 Susceptibility testing by MIC evaluation was performed for carbapenem-
resistant K. pneumoniae and E. coli strains, for ertapenem-resistant E. coli strains 
and for cephalosporin-resistant K. pneumoniae.  
The carbapenems, cephalosporins and aztreonam MICs distribution in 
totally 163 carbapenem-resistant K. pneumoniae strains are shown in graph. 2 and 
3. 
Carbapenem MICs ranged from 4 μg/ml to >128 μg/ml for imipenem and 
meropenem and from 16 μg/ml to >128 μg/ml for ertapenem. Cephalosporins MICs 
ranged from 16 μg/ml to >128 μg/ml for cefotaxime and cefepime; all strains had 
ceftazidime MIC ≥128 μg/ml.  
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Graph. 2 Carbapenems MICs distribution in totally 163 carbapenem-resistant K. 
pneumoniae strains. (IMI=Imipenem; MERO=Meropenem; ERTA=Ertapenem) 
 69 
 
 
 
The MICs distribution in totally 14 carbapenem-resistant E. coli strains are 
shown in graph. 4 and 5. 
Carbapenem MICs ranged from 0.25 μg/ml to 4 μg/ml for imipenem; from 
0.25 μg/ml to 8 μg/ml for meropenem, and from 1 μg/ml to 32 μg/ml for ertapenem. 
Cefotaxime and cefepime MICs ranged from 16 μg/ml to >128 μg/ml, and all strains 
had ceftazidime MIC ≥128 μg/ml. 
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Graph. 3 Cephalosporins and aztreonam MICs distribution in totally 163 carbapenem-
resistant K. pneumoniae strains. (CTX=Cefotaxime; CTZ=Ceftazidime; FEP=Cefepime; 
AZT=Aztreonam) 
Graph. 4 Carbapenems MICs distribution in 14 carbapenem-resistant E. coli strains.  
(IMI=Imipenem; MERO=Meropenem; ERTA=Ertapenem) 
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Carbapenems MICs in 4 ertapenem-resistant E. coli strains had different 
range: from 0.12 μg/ml and 0.5 μg/ml for imipenem; from <0.06 μg/ml to 8 μg/ml 
for meropenem, and from 0.5 μg/ml to 64 μg/ml for ertapenem. Cephalosporins 
MICs ranged from 64 μg/ml to >128 μg/ml for ceftazidime; all strains had MIC 
≥128 for cefepime and >128 for cefotaxime and aztreonam. 
Cephalosporins MICs distribution in totally 54 cephalosporin-resistant K. 
pneumoniae strains are shown in graph. 6. Cefotaxime MICs ranged from 0.5 μg/ml 
to >128 μg/ml; ceftazidime from 1 μg/ml to >128 μg/ml, and cefepime from 0.25 
μg/ml to >128 μg/ml. MIC range for aztreonam is from 0.5 μg/ml to >128 μg/ml. 
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Graph. 5 Cephalosporins and aztreonam MICs distribution in totally 14 carbapenem-
resistant E. coli strains. (CTX=Cefotaxime; CTZ=Ceftazidime; FEP=Cefepime; 
AZT=Aztreonam) 
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 PCR amplification for bla genes showed:  
 Carbapenem-resistant K. pneumoniae strains from Verona: 95 (100%) 
identified as possible KPC producers by positive Carba NP test. By PCR, all carried 
blaKPC gene, and 1 strain (1.05%) also co-carried a blaVIM gene. All were negative 
for blaIMP, blaNDM, or blaOXA-48. Two out of 95 strains (2.1%) carried only blaKPC 
gene; 69 (72.6%) co-carried blaKPC and blaTEM; 1 (1.05%) co-carried blaKPC, blaVIM 
and blaTEM; 21 (22.1%) blaKPC, blaTEM and blaSHV; 1 (1.05%) co-carried blaKPC, 
blaTEM and blaCTX-M-1; 1 (1.05%) co-carried blaKPC and blaSHV. [Tab.15] 
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Graph. 6 Cephalosporins and aztreonam MICs distribution in totally 54 cephalosporin-
resistant K. pneumoniae strains. (CTX=Cefotaxime; CTZ=Ceftazidime; FEP=Cefepime; 
AZT=Aztreonam) 
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Strain Carba  
Test  
KPC  VIM IMP NDM OXA-
48 
TEM SHV OXA-1  CTX-
M-1 
CTX-
M-2 
CTX-
M-9 
CTX-M-
8/25 
MDR4 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR6 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR10 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR11 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR12 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR20 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR21 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR22 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR25 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR31 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR34 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR37 Pos Pos Neg Neg Neg Neg Pos Neg Neg Pos Neg Neg Neg 
MDR38 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR50 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR53 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR56 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR57 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR59 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR76 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR88 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR96 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR97 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR98 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR102 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR105 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR107 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR128 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR130 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR133 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR136 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR154 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
Tab. 15 Results of Carba NP test and PCRs for bla genes in 95 carbapenem-resistant K. pneumoniae strains from 
Verona Hospital 
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Strain Carba 
Test  
KPC  VIM IMP NDM OXA-
48 
TEM SHV OXA-1  CTX-
M-1 
CTX-
M-2 
CTX-
M-9 
CTX-M-
8/25 
MDR172 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR173 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR174 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR175 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR183 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR208 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR235 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR250 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR259 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR271 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR279 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR285 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR295 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR300 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR303 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR305 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR315 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
MDR323 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
MDR332 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR339 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR345 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR350 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
MDR352 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR358 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
MDR363 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR367 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR386 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR396 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR400 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
MDR403 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
MDR404 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
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Strain Carba 
Test  
KPC  VIM IMP NDM OXA-
48 
TEM SHV OXA-1  CTX-
M-1 
CTX-
M-2 
CTX-
M-9 
CTX-M-
8/25 
MDR409 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR420 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR427 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
MDR428 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
MDR430 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
MDR436 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
MDR443 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR452 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR454 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR463 Pos Pos Neg Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg 
MDR464 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
MDR471 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
MDR473 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
MDR480 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR485 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR488 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR494 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR506 Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg 
MDR508 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR515 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR516 Pos Pos Pos Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR518 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR567 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
MDR574 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
MDR582 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
MDR587 Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg 
MDR588 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR593 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
MDR597 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
MDR614 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
MDR624 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
Pos, positive; Neg, negative 
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 Carbapenem-resistant E. coli strains from Verona: 4 out of 5 (80%) 
identified as possible KPC producers by positive Carba NP test. Four out of 5 (80%) 
harbored blaKPC gene and 1 (20%) blaVIM. None were positive for blaIMP, blaNDM, 
or blaOXA-48. Three strains (60%) co-carried blaKPC and blaTEM; 1 (20%) blaKPC, 
blaTEM, blaCTX-M-2 and blaCTX-M-9; 1 (20%) blaVIM and blaTEM. [Tab. 16] 
 
Strain Carba 
Test  
KPC  VIM IMP NDM OXA-48 TEM SHV OXA-
1  
CTX-
M-1 
CTX-
M-2 
CTX-
M-9 
CTX-M-
8/25 
MDR219 Neg Neg Pos Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR368 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Pos Pos Neg 
MDR434 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR600 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
MDR646 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
              
 
 Ertapenem-resistant E. coli strains from Verona Hospital: 4 strains all 
negative for Carba NP Test and positive for ESBL NDP Test. All were negative for 
carbapenemase genes PCR, but co-carried blaOXA-1 and blaCTX-M-1. [Tab. 17] 
 
Strain Carba 
Test  
KPC  VIM IMP NDM OXA-
48 
TEM SHV OXA-1  CTX-
M-1 
CTX-
M-2 
CTX-
M-9 
CTX-M-
8/25 
MDR135 Neg Neg Neg Neg Neg Neg Neg Neg Pos Pos Neg Neg Neg 
MDR162 Neg Neg Neg Neg Neg Neg Neg Neg Pos Pos Neg Neg Neg 
MDR220 Neg Neg Neg Neg Neg Neg Neg Neg Pos Pos Neg Neg Neg 
MDR412 Neg Neg Neg Neg Neg Neg Neg Neg Pos Pos Neg Neg Neg 
              
 
Tab. 16 Results of Carba NP test and PCRs for bla genes in 5 carbapenem-resistant E. coli strains from Verona Hospital 
Tab. 17 Results of Carba NP test and PCRs for bla genes in 4 ertapenem-resistant E. coli strains from Verona 
Hospital 
Pos, positive; Neg, negative 
Pos, positive; Neg, negative 
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 Cephalosporin-resistant K. pneumoniae strains from Verona Hospital: 23 
out of 24 strains (95.8%) identified as possible ESBL-producers by positive ESBL 
NDP test; all were negative for Carba NP test. None carried carbapenemase genes. 
Five out of 24 (20.8%) carried blaTEM gene; 1 (4.2%) blaSHV; 1 (4.2%) blaOXA-1; 3 
(12.5%) blaCTX-M-1; 1 (4.2%) co-carried blaTEM and blaCTX-M-1; 1 (4.2%) blaSHV and 
blaCTX-M-1; 5 (20.8%) blaTEM, blaOXA-1 and blaCTX-M-1; 1 (4.2%) blaTEM, blaCTX-M-1, 
blaCTX-M-2 and blaCTX-M-9; 1 (4.2%) blaTEM, blaSHV, blaCTX-M-1, blaCTX-M-2 and blaCTX-
M-9; 5 (20.8%) carried none of bla genes investigated. [Tab. 18] 
 
 
Strain Carba 
Test  
ESBL 
Test 
TEM SHV OXA-1  CTX-
M-1 
CTX-
M-2 
CTX-
M-9 
CTX-M-
8/25 
MDR29 Neg Pos Neg Neg Neg Neg Neg Neg Neg 
MDR39 Neg Pos Neg Neg Pos Neg Neg Neg Neg 
MDR66 Neg Pos Neg Neg Neg Neg Neg Neg Neg 
MDR108 Neg Pos Neg Neg Neg Pos Neg Neg Neg 
MDR121 Neg Pos Pos Neg Neg Neg Neg Neg Neg 
MDR137 Neg Pos Neg Neg Neg Pos Neg Neg Neg 
MDR255 Neg Pos Pos Neg Neg Pos Neg Neg Neg 
MDR276 Neg Pos Pos Neg Pos Pos Neg Neg Neg 
MDR277 Neg Pos Pos Neg Neg Neg Neg Neg Neg 
MDR293 Neg Pos Pos Neg Pos Pos Neg Neg Neg 
MDR312 Neg Pos Pos Neg Neg Pos Pos Pos Neg 
MDR313 Neg Pos Pos Pos Neg Pos Pos Pos Neg 
MDR329 Neg Pos Pos Neg Pos Pos Neg Neg Neg 
MDR381 Neg Pos Neg Neg Neg Pos Neg Neg Neg 
MDR419 Neg Pos Pos Neg Pos Pos Neg Neg Neg 
MDR424 Neg Pos Neg Neg Neg Neg Neg Neg Neg 
MDR433 Neg Pos Neg Neg Neg Neg Neg Neg Neg 
MDR447 Neg Neg Neg Neg Neg Neg Neg Neg Neg 
MDR478 Neg Pos Pos Neg Neg Neg Neg Neg Neg 
MDR496 Neg Pos Pos Neg Pos Pos Neg Neg Neg 
MDR500 Neg Pos Pos Neg Neg Neg Neg Neg Neg 
MDR527 Neg Pos Pos Neg Neg Neg Neg Neg Neg 
MDR546 Neg Pos Neg Pos Neg Neg Neg Neg Neg 
MDR559 Neg Pos Neg Pos Neg Pos Neg Neg Neg 
 
 
Tab. 18 Results of Carba NP test, ESBL NDP test and PCRs for bla genes in 24 
cephalosporin-resistant K. pneumoniae strains from Verona Hospital 
Pos, positive; Neg, negative 
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 Carbapenem-resistant K. pneumoniae strains from Negrar Hospital: all 68 
strains resulted positive at Carba NP test. All carried blaKPC gene, none carried other 
carbapenemase genes. Two out of 68 strain (2.9%) carried only blaKPC gene; 34 
(50%) co-carried blaKPC and blaTEM; 31 (45.6%) blaKPC, blaTEM and blaSHV; 1 
(1.5%) co-carried blaKPC, blaTEM and blaCTX-M-2. [Tab. 19] 
 
 
Strain Carba  
Test  
KPC  VIM IMP NDM OXA-
48 
TEM SHV OXA-1  CTX-
M-1 
CTX-
M-2 
CTX-
M-9 
CTX-M-
8/25 
N5 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N6 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N7 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N15 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N28 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N29 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N45 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N46 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N50 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N54 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N57 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N62 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N63 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N72 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N79 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N87 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N90 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N92 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N98 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N110 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N111 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N114 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N132 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Pos Neg Neg 
Tab. 19 Results of Carba NP test and PCRs for bla genes in 68 carbapenem-resistant K. pneumoniae strains from Negrar 
Hospital 
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Strain Carba  
Test  
KPC  VIM IMP NDM OXA-
48 
TEM SHV OXA-1  CTX-
M-1 
CTX-
M-2 
CTX-
M-9 
CTX-M-
8/25 
N134 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N135 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N141 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N142 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N143 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N148 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N149 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N156 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N165 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N166 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N180 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N181 Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg 
N187 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N188 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N191 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N205 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N207 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N210 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N217 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N224 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N225 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N227 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N236 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N253 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N258 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N263 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N276 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N282 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N287 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N290 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N291 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
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Strain Carba  
Test  
KPC  VIM IMP NDM OXA-
48 
TEM SHV OXA-1  CTX-
M-1 
CTX-
M-2 
CTX-
M-9 
CTX-M-
8/25 
N292 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N293 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N298 Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg 
N326 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N334 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N347 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N349 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N353 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N367 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N368 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N369 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N378 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N379 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N383 Pos Pos Neg Neg Neg Neg Pos Neg Neg Neg Neg Neg Neg 
 
 Carbapenem-resistant E. coli strains from Negrar: 8 out of 9 (88.8%) were 
positive to Carba NP test, 1 gave an unclear result and was considered doubtful. All 
strains harbored blaKPC gene, none carried other carbapenemase genes.  Eight out 
of 9 strains (88.8%) co-carried blaKPC, blaTEM and blaCTX-M-1; 1 (11.1%) blaKPC, 
blaTEM, blaSHV. [Tab. 20] 
 
Strain Carba 
Test  
KPC  VIM IMP NDM OXA-
48 
TEM SHV OXA-
1  
CTX-
M-1 
CTX-
M-2 
CTX-
M-9 
CTX-M-
8/25 
N256 Pos Pos Neg Neg Neg Neg Pos Neg Neg Pos Neg Neg Neg 
N257 Pos Pos Neg Neg Neg Neg Pos Neg Neg Pos Neg Neg Neg 
N328 Pos Pos Neg Neg Neg Neg Pos Neg Neg Pos Neg Neg Neg 
N354 Doub Pos Neg Neg Neg Neg Pos Neg Neg Pos Neg Neg Neg 
N370 Pos Pos Neg Neg Neg Neg Pos Neg Neg Pos Neg Neg Neg 
N375 Pos Pos Neg Neg Neg Neg Pos Neg Neg Pos Neg Neg Neg 
N376 Pos Pos Neg Neg Neg Neg Pos Neg Neg Pos Neg Neg Neg 
N380 Pos Pos Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N381 Pos Pos Neg Neg Neg Neg Pos Neg Neg Pos Neg Neg Neg 
              
Tab. 20 Results of Carba NP test and PCRs for bla genes in 9 carbapenem-resistant E. coli strains from Negrar Hospital 
Pos, positive; Neg, negative 
Pos, positive; Neg, negative; Doub, doubtful 
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 Cephalosporin-resistant K. pneumoniae strains from Negrar Hospital: 30 
strains, all negative for Carba NP test; 24 out of 30 (80%) were identified as 
possible ESBL producers by positive ESBL NDP test. By PCR, 3 out of 30 (10%) 
carried blaTEM gene; 3 (10%) blaSHV; 1 (3.33%) blaCTX-M-1; 2 out of 30(6.67%) co-
carried blaTEM and blaSHV; 2 (6.67%) blaTEM, blaSHV and blaCTX-M-1; 6 (20%) co-
carried blaTEM, blaOXA-1 and blaCTX-M-1; 3 (10%) blaOXA-1 and blaCTX-M-1; 1(3.33%) 
blaSHV and blaCTX-M-1; 4 (13.3%) blaTEM, blaSHV, blaOXA-1 and blaCTX-M-1; 5 (16.6%) 
blaSHV, blaOXA-1 and blaCTX-M-1. [Tab. 21] 
 
 
Strain Carba 
Test  
ESBL 
Test  
TEM SHV OXA-1  CTX-
M-1 
CTX-
M-2 
CTX-
M-9 
CTX-M-
8/25 
N11 Neg Pos Pos Neg Pos Pos Neg Neg Neg 
N16 Neg Pos Neg Neg Pos Pos Neg Neg Neg 
N39 Neg Pos Pos Pos Pos Pos Neg Neg Neg 
N40 Neg Pos Pos Pos Neg Pos Neg Neg Neg 
N42 Neg Pos Pos Pos Pos Pos Neg Neg Neg 
N52 Neg Pos Neg Pos Pos Pos Neg Neg Neg 
N88 Neg Pos Pos Pos Pos Pos Neg Neg Neg 
N89 Neg Pos Pos Neg Pos Pos Neg Neg Neg 
N95 Neg Pos Pos Neg Pos Pos Neg Neg Neg 
N101 Neg Pos Pos Neg Pos Pos Neg Neg Neg 
N102 Neg Pos Neg Pos Neg Pos Neg Neg Neg 
N104 Neg Pos Neg Pos Pos Pos Neg Neg Neg 
N113 Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N126 Neg Neg Neg Pos Neg Neg Neg Neg Neg 
N138 Neg Pos Pos Pos Neg Pos Neg Neg Neg 
N139 Neg Neg Pos Neg Neg Neg Neg Neg Neg 
N220 Neg Pos Pos Neg Pos Pos Neg Neg Neg 
N237 Neg Neg Pos Pos Neg Neg Neg Neg Neg 
N246 Neg Pos Neg Pos Pos Pos Neg Neg Neg 
N289 Neg Pos Neg Pos Pos Pos Neg Neg Neg 
N297 Neg Neg Neg Pos Neg Neg Neg Neg Neg 
N301 Neg Pos Pos Pos Pos Pos Neg Neg Neg 
N304 Neg Pos Neg Pos Pos Pos Neg Neg Neg 
Tab. 21 Results of Carba NP test, ESBL NDP test and PCRs for bla genes in 24 
cephalosporin-resistant K. pneumoniae strains from Negrar Hospital 
Pos, positive; Neg, negative 
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 The analysis of PCR results for totality carbapenem-resistant K. 
pneumoniae strain showed that all strains harboring blaKPC gene, but the 
combination blaKPC and blaTEM is prevalent 103 out of 163 (63.2%); 52 out of 163 
strains (31.9%) carried blaKPC/blaTEM/blaSHV; 4 (2.4%) carried only blaKPC; 1 
(0.6%) blaKPC/blaSHV; 1 (0.6%) carried blaKPC/blaVIM/blaTEM; 1 (0.6%) 
blaKPC/blaTEM/blaCTX-M-1; 1 (0.6%) blaKPC/blaTEM/blaCTX-M-2. [Graph. 7] 
 
 
 Totally carbapenem-resistant E. coli strains showed that prevalent 
combination is blaKPC/blaTEM/blaCTX-M-1 carried by 8 out of 14 (57.1%); blaKPC and 
blaTEM is carried by 3 out of 14 (21.4%); 1 (7.1%) carried blaVIM and blaTEM; 1 
(7.1%) blaKPC/blaTEM/blaSHV; 1 (7.1%) blaKPC/blaTEM/blaCTX-M-1/blaCTX-M-9. [Graph. 
8] 
 
Distribution of carbapenemase in total 
carbapenem-resistant K. pneumoniae strains
KPC+TEM KPC+TEM+SHV KPC
KPC+SHV KPC+VIM+TEM KPC+TEM+CTXM1
KPC+TEM+CTXM2
Distribution of carbapenemase in total 
carbapenem-resistant E. coli strains
KPC+TEM+CTXM1 KPC+TEM
VIM+TEM KPC+TEM+SHV
KPC+TEM+CTXM1+CTXM9
Graph. 7 Distribution of carbapenemase genes in total 163 carbapenem-resistant K. 
pneumoniae strains. 
Graph. 8 Distribution of carbapenemase genes in total 14 carbapenem-resistant E. coli strains. 
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 Distribution of ESBL genes between totally cephalosporin-resistant K. 
pneumoniae strains is broader. The prevalent combination is blaTEM/blaOXA-
1/blaCTXM-1 in 11 out 54 strains (20.4%); 8 strains (14.8%) carried blaTEM; 5 (9.2%) 
co-carried blaSHV/blaOXA-1/blaCTXM-1; 4 (7.4%) blaSHV; 4 (7.4%) blaCTXM-1; 4 (7.4%)  
blaTEM/blaSHV/blaOXA-1/blaCTXM-1; 3 (5.5%) blaOXA-1/blaCTXM-1; 2 (3.7%) blaTEM/ 
blaSHV; 2 (3.7%) blaSHV/blaCTX-M-1; 2 (3.7%) blaTEM/blaSHV/blaCTX-M-1; 1 (1.8%) 
blaOXA-1; 1 (1.8%) blaTEM/blaCTX-M-1; 1 (1.8%) blaTEM/blaCTX-M-1/blaCTX-M-2/blaCTX-
M-9; 1 (1.8%) blaTEM/ blaSHV/blaCTX-M-1/blaCTX-M-2/blaCTX-M-9. [Graph. 9] 
 
 
 After confirmation of resistance profile, carbapenemase or ESBL-
production and detection of bla genes carried, we evaluated the correlation between 
KPC production and 11,109Da (±8Da) peak [Fig. 38] on MALDI-TOF MS spectra.  
 
 
 
 
ESBL distribution in cephalosporin-resistant K. 
pneumoniae strains
TEM+OXA1+CTXM1 TEM
SHV+OXA1+CTXM1 None
SHV CTXM1
TEM+SHV+OXA1+CTXM1 OXA1+CTXM1
TEM+SHV SHV+CTXM1
TEM+SHV+CTXM1 OXA1
TEM+CTXM1 TEM+CTXM1+CTXM2+CTXM9
TEM+SHV+CTXM1+CTXM2+CTXM9
Graph. 9 Distribution of ESBL genes in total 54 cephalosporin-resistant K. pneumoniae strains. 
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Spectra of all strains above mentioned, performed in duplicate, were 
analyzed to detect the 11,109Da peak. The spectra analysis was repeated for 
discrepant strains (strains resulted positive for blaKPC, but negative for the 11,109Da 
peak) after re-isolation. Results of spectra analysis are summarized in Tab. 22 and 
23. 
 
  11,109Da peak   
  First MALDI-TOF 
spectra analysis  
After retested 
discrepant 
 
  Present Absent Tot Present Absent Tot 
KPC producers  
KPN Verona 94 1 95 95 0 95 
KPN Negrar 67 1 68 67 1 68 
ECO Verona 3 1 4 4 0 4 
ECO Negrar 9 0 9 9 0 9 
ESBL producers or 
Ertapenem-resistant 
KPN Verona 0 24 24 0 24 24 
KPN Negrar 0 30 30 0 30 30 
 ECO Verona 0 4 4 0 4 4 
Fig. 38 MALDI-TOF MS spectrum of KPC-producing bacterial strain with the 11,109Da peak. 
Tab. 22 Results of first MALDI-TOF MS spectra analysis and of repeated spectra analysis of discrepant, on 
KPC-producing and ESBL-producing or Ertapenem-resistant strains distinguished for provenience  
KPN, K. pneumoniae; ECO, E. coli 
11,109Da 
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  11,109Da peak   
  First MALDI-TOF 
spectra analysis  
After retested 
discrepant 
 
  Present Absent Tot Present Absent Tot 
KPC producers  
KPN 161 2 163 162 1 163 
ECO 12 1 13 13 0 13 
ESBL producers or 
Ertapenem-
resistant 
 KPN 0 54 54 0 54 54 
ECO  0 4 4 0 4 4 
  
  
 At the first MALDI-TOF MS spectra analysis 161 on 163 (98.7%) KPC-
producing K. pneumoniae (KPN) strains, and 12 on 13 (92.3%) KPC-producing E. 
coli (ECO) strains were positive for 11,109Da peak.  
 All 58 cephalosporin-resistant or ertapenem-resistant strains were negative 
for the presence of the same peak. 
 On discrepant strains, that are the strains positive for blaKPC by PCR 
detection and negative at MALDI-TOF MS analysis for 11,109 Da peak, we 
repeated MALDI-TOF measurements after re-isolation on MH plate. After this, two 
more strains, namely 1 K. pneumoniae and 1 E. coli, showed the 11,109Da peak in 
their spectra, increasing the sensitivity to 99.4% (162/163) and 100% (13/13) 
respectively. [Tab. 23] Only 1 K. pneumoniae out of 176 KPC-producing strains 
(0.56%), the N181 strain, was confirmed to be discrepant. [Tab. 19] [Tab.22 and 
23] 
 MALDI-TOF MS measurement of N181 strain was repeated in duplicate 
after 4 passages on MH agar plates containing Imipenem (2 mg/ml) in order to 
increase expression of carbapenemase. Spectra analysis confirmed anyway the 
absence of the peak. Multiplex and simplex PCRs for blaIMP/blaVIM/blaKPC and 
blaNDM 
[78] were repeated confirming blaKPC presence. The blaKPC PCR product was 
Tab. 23 Results of MALDI-TOF MS spectra analysis on totally KPC-producing and ESBL-producing 
or Ertapenem-resistant strains, before and after retested discrepant 
KPN, K. pneumoniae; ECO, E. coli 
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purified and sequenced. The sequence analyses proved that the strain harbored a 
bla gene encoding for KPC-3 enzyme. Also for this discrepant strain we performed 
plasmid extraction and characterization [56] [79] and resulted the strain harbored an 
OriColE plasmid only. [Tab. 27 and 28] 
 
 We performed MALDI-TOF MS analysis in duplicate and spectra analysis 
also on selected strains control groups: K. pneumoniae susceptible to β-lactams; 
ESBL-producing E. coli; NDM-producing and VIM-producing 
Enterobacteriaceae. All strains of control groups were negative for blaKPC gene and 
were negative for 11,109Da peak on MALDI-TOF MS spectra too. [Tab. 24]  
 
 
  
 
 
 
 
  
 We performed MALDI-TOF MS spectra analysis also on positive and 
negative control strains [Tab. 8] and only MALDI-TOF spectrum of KPC positive 
control showed the 11,109Da peak.  
 
 
 
 
 11,109Da peak  
 Present Absent Tot 
ECO ESBL 0 121 121 
KPN S 0 27 27 
NDM strains 0 15 15 
VIM strains 0 39 39 
Tab. 24 Results of MALDI-TOF MS spectra analysis on selected control groups; ESBL-
producing, NDM-producing, VIM-producing and susceptible to β-lactams strains 
KPN, K. pneumoniae; ECO, E. coli; S, susceptible  
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Novel variant of KPC enzyme emerging between Group 1 strains  
Between the strains of Group 1 we found three K. pneumoniae strains 
(MDR53, MDR136 and MDR345) isolated from screening samples of a patient 
candidate for liver transplantation and who had undergone selective digestive 
decontamination. The first strain was isolated before transplantation and the two 
others after decontamination and transplantation. All three strains were positive for 
Carba NP test; MICs for meropenem, imipenem and ertapenem were higher than 
128 µg/ml. MIC for colistin was 0.5 µg/ml and for tigecycline was 1 µg/ml, all 
strains were susceptible to gentamycin (MIC 1 µg/ml). The strains carried blaKPC 
gene, and the PCR products were sequenced and analyzed with Blast at the Pub-
Med site. [91] The sequence showed a N291T substitution compared to the blaKPC-3 
gene endemic in our hospital. [82] [Fig. 39] The mutated sequence encoded for a 
novel enzyme that was named KPC-19 at http:/www.lahey.org/studies and 
accession number of GenBank is KJ775801. [50] [91] These three strains harbored 
OriColE and IncFII plasmids by using PCR based-replicon typing (PBRT) 
according to Carattoli et al. [56] [79] Also, conjugation with MDR53 as donor and E. 
coli J53 as recipient was performed successfully. 
                                   CTGGCTGGCTTTTCTGCCACCGCGCTGACCAACCTCGTCGCGGAACCATTCGCTAAACTC  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7111  CTGGCTGGCTTTTCTGCCACCGCGCTGACCAACCTCGTCGCGGAACCATTCGCTAAACTC  
7170 
 
Query  61    GAACAGGACTTTGGCGGCTCCATCGGTGTGTACGCGATGGATACCGGCTCAGGCGCAACT  
120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7171  GAACAGGACTTTGGCGGCTCCATCGGTGTGTACGCGATGGATACCGGCTCAGGCGCAACT  
7230 
 
Query  121   GTAAGTTACCGCGCTGAGGAGCGCTTCCCACTGTGCAGCTCATTCAAGGGCTTTCTTGCT  
180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7231  GTAAGTTACCGCGCTGAGGAGCGCTTCCCACTGTGCAGCTCATTCAAGGGCTTTCTTGCT  
7290 
 
Query  181   GCCGCTGTGCTGGCTCGCAGCCAGCAGCAGGCCGGCTTGCTGGACACACCCATCCGTTAC  
240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7291  GCCGCTGTGCTGGCTCGCAGCCAGCAGCAGGCCGGCTTGCTGGACACACCCATCCGTTAC  
7350 
 
Query  241   GGCAAAAATGCGCTGGTTCCGTGGTCACCCATCTCGGAAAAATATCTGACAACAGGCATG  
300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
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Sbjct  7351  GGCAAAAATGCGCTGGTTCCGTGGTCACCCATCTCGGAAAAATATCTGACAACAGGCATG  
7410 
 
Query  301   ACGGTGGCGGAGCTGTCCGCGGCCGCCGTGCAATACAGTGATAACGCCGCCGCCAATTTG  
360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7411  ACGGTGGCGGAGCTGTCCGCGGCCGCCGTGCAATACAGTGATAACGCCGCCGCCAATTTG  
7470 
 
Query  361   TTGCTGAAGGAGTTGGGCGGCCCGGCCGGGCTGACGGCCTTCATGCGCTCTATCGGCGAT  
420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7471  TTGCTGAAGGAGTTGGGCGGCCCGGCCGGGCTGACGGCCTTCATGCGCTCTATCGGCGAT  
7530 
 
Query  421   ACCACGTTCCGTCTGGACCGCTGGGAGCTGGAGCTGAACTCCGCCATCCCAGGCGATGCG  
480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7531  ACCACGTTCCGTCTGGACCGCTGGGAGCTGGAGCTGAACTCCGCCATCCCAGGCGATGCG  
7590 
 
Query  481   CGCGATACCTCATCGCCGCGCGCCGTGACGGAAAGCTTACAAAAACTGACACTGGGCTCT  
540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7591  CGCGATACCTCATCGCCGCGCGCCGTGACGGAAAGCTTACAAAAACTGACACTGGGCTCT  
7650 
 
Query  541   GCACTGGCTGCGCCGCAGCGGCAGCAGTTTGTTGATTGGCTAAAGGGAAACACGACCGGC  
600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7651  GCACTGGCTGCGCCGCAGCGGCAGCAGTTTGTTGATTGGCTAAAGGGAAACACGACCGGC  
7710 
 
Query  601   AACCACCGCATCCGCGCGGCGGTGCCGGCAGACTGGGCAGTCGGAGACAAAACCGGAACC  
660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7711  AACCACCGCATCCGCGCGGCGGTGCCGGCAGACTGGGCAGTCGGAGACAAAACCGGAACC  
7770 
 
Query  661   TGCGGAGTGTATGGCACGGCAAATGACTATGCCGTCGTCTGGCCCACTGGGCGCGCACCT  
720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7771  TGCGGAGTGTATGGCACGGCAAATGACTATGCCGTCGTCTGGCCCACTGGGCGCGCACCT  
7830 
 
Query  721   ATTGTGTTGGCCGTCTACACCCGGGCGCCTAACAAGGATGACAAGTACAGCGAGGCCGTC  
780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  7831  ATTGTGTTGGCCGTCTACACCCGGGCGCCTAACAAGGATGACAAGTACAGCGAGGCCGTC  
7890 
 
Query  781   ATCGCCGCTGCGGCTAGACTCGCGCTCGAGGGATTGGGCGTCACGGGGCAGTAAAA  
836 
             |||||||||||||||||||||||||||||||||||||||||||  ||||||||||| 
Sbjct  7891  ATCGCCGCTGCGGCTAGACTCGCGCTCGAGGGATTGGGCGTCAACGGGCAGTAAAA  
7946 
 
 
Fig. 39 blaKPC sequence of MDR53 K. pneumoniae strain compared with KPC-3 sequence, showing 
N291T substitution. [50] 
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b. Spectra analysis to evaluate the use in clinical diagnostic workflow of 
11,109Da peak detection 
 
Group 2  
 To evaluate the utility and the feasibility of the 11,109Da peak detection for 
KPC producers screening in clinical lab, we analyzed daily from May to July 2016 
the MALDI-TOF MS spectra of strains investigated for carbapenemase production. 
 Three technicians working on MDR screening had performed the MALDI-
TOF MS identification of bacterial strains isolated during usual routine work and 
we analyzed their spectra to detect the 11,109Da peak. 
 Over three months, we analyzed the spectra of 183 strains, namely 171 K. 
pneumoniae, 9 E. coli, 2 Enterobacter aerogenes, 1 Enterobacter cloacae, isolated 
on ChomeID ESBL (bioMérieux) agar plates with Ertapenem (10 µg) disk and 
either positive at Carba NP test or positive at ESBL NDP test. 
 At the first MALDI-TOF MS spectra analysis 121 out of 135 (89,63%) 
Carba NP positive strains, were positive also for the 11,109Da peak. The same peak 
was absent in all 48 positive strains for ESBL NDP test only. 
 We repeated the MALDI-TOF MS identification on discrepant strains after 
re-isolation on MH plates and 8 more strains positive for Carba NP test showed the 
11,109Da peak in their spectrum, increasing the sensitivity to 95,5% (129/135). 
[Tab. 25] 
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                                   11,109Da peak     
   First MALDI-TOF 
spectra analysis  
 Spectra analysis after 
repetition of discrepant 
strains  
   Present Absent Tot Present Absent Tot 
Carba NP 
test 
positive 
K. pneumoniae  114 10 124 122 2 124 
E. coli  6 2 8 6 2 8 
E. aerogenes  1 1 2 1 1 2 
E. cloacae  0 1 1 0 1 1 
ESBL 
NDP test 
positive 
K. pneumoniae  0 47 47 0 47 47 
E. coli  0 1 1 0 1 1 
 
 On 6 discrepant strains, positive for Carba NP test, but negative for the 
11,109Da peak, MALDI-TOF MS identification was repeated in duplicate after 4 
passages on MH agar plates additioned with imipenem (2 mg/ml), but spectra 
analysis confirms absence of the peak.  
 Multiplex and simplex PCRs for blaIMP/blaVIM/blaKPC and blaNDM 
[78] were 
performed on the 6 discrepant strains. Only 3 strains resulted positive for blaKPC, 
while 3 strains produce other carbapenemases, namely 1 NDM (E. coli) and 2 VIM 
(1 E. aerogenes, 1 E. cloacae).   
 These results showed that 132 out of 135 carbapenemase producers, were 
KPC producers and increased the sensitivity of MALDI-TOF MS detection to 
97,7% (129/132). The discrepant strains on this group were only 3 (2.2%), namely: 
2 K. pneumoniae (87/24U and MDR4597), 1 E. coli (MDR4547). [Tab. 27 and 28] 
 The amplicon of the three positive blaKPC discrepant strains were purified 
and sequenced. Analysis of the sequences showed the gene encoding for two KPC-
19 and 1 KPC-3 enzymes. Plasmid extraction and characterization [56] [79] were 
performed and proved 1 strain positive for OriColE and IncR, 1 positive for IncFIA 
and IncFIB, and 1 positive for IncQ. [Tab. 27 and 28] 
Tab. 25 Results of MALDI-TOF MS spectra analysis on strains with Carba NP test or ESBL NDP test 
positive isolated during routinely screening from May to July 2016. On discrepant strains MALDI-TOF 
measurement was repeated after re-isolation 
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c. Spectra analysis of collection strains to find NDM-producing E. coli  
Group 3 
 After detection of one NDM-producing E. coli strain amongst the routine 
samples, namely: MDR18/12 (Group 2), we performed a retrospective analysis on 
carbapenemase-producing E. coli strains, to detect other NDM producers.  
 We investigated 11 E. coli strains positive for Carba NP test, isolated during 
MDR screening from January to November 2015. The strains were plated from 
frozen stock on MH agar plates, MALDI-TOF MS measurements in duplicate and 
multiplex and simplex PCRs for blaIMP/blaVIM/blaKPC and blaNDM 
[78] were 
performed. The spectra analysis showed that in 2 out of 11 strains, the 11,109Da 
peak was absent; all strains resulted positive for blaKPC. [Tab. 26] 
 
 
 
 
 
 
 
 
 
 
 
 
 
Strain Carba Test  11,109DA peak KPC  VIM IMP NDM 
MDR1696 Pos 11,113 Pos Neg Neg Neg 
MDR1997 Pos 11,110 Pos Neg Neg Neg 
MDR2114 Pos Absent Pos Neg Neg Neg 
MDR2225 Pos 11,111 Pos Neg Neg Neg 
MDR2247 Pos 11,111 Pos Neg Neg Neg 
MDR2270 Pos 11,107 Pos Neg Neg Neg 
MDR2367 Pos 11,115 Pos Neg Neg Neg 
MDR2440 Pos 11,110 Pos Neg Neg Neg 
MDR2489 Pos 11,107 Pos Neg Neg Neg 
MDR2664 Pos 11,110 Pos Neg Neg Neg 
MDR2984 Pos Absent Pos Neg Neg Neg 
Tab. 26 Carbapenemase-producing E. coli strains from collection investigated for blaNDM gene 
Pos, positive; Neg, negative 
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 MALDI-TOF MS identification was repeated for the 2 discrepant strains 
after streaking on MH plates plus Imipenem (2mg/ml), confirming the strains were 
discrepant. They were namely: MDR2114 and MDR2984. The blaKPC amplicons 
were purified and sequenced, both resulting for KPC-19. Plasmid extraction and 
characterization were performed, 1 strain resulting positive for IncN, IncFIB and 
IncFrepB replicons and the second negative for all Inc/rep investigated. [Tab. 27 
and 28]   
 
 
d. Discrepant strains analysis 
Through MALDI-TOF MS spectra analysis of the above mentioned three 
sample groups, we found 6 discrepant strains, positive for blaKPC, but negative for 
the 11,109Da peak. Other 2 discrepant strains were detected in Group 5 after spectra 
analysis to detect the 11,109Da peak, namely MDR1958 and MDR2025. 
Totally, we found 8 discrepant strains out of 362 (2.2%) KPC-producing 
Enterobacteria strains. Three strains were E. coli and 5 were K. pneumoniae. 
We investigated the correlation between the peak absence and the plasmid 
profile of the discrepant strains carrying a blaKPC gene. On table 27 and 28 the 
results of blaKPC sequencing and plasmid characterization for all discrepant strains 
are summarized.  
The strains differed from each other for plasmid profile, namely: N181, 
MDR1958 and MDR2025 had positive OriColE; 87/24U IncR and OricolE; 
MDR4547 FIA and FIB; MDR4597 IncQ; MDR2114 N, FIB and FrepB; 
MDR2984 not at all. Two out of 8 strains: N181, MDR4547 were harboring KPC-
3, the others were harboring KPC-19 enzyme. 
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Strain Sequence IncQ IncR IncU OriColE 
N181 KPN KPC-3  Neg Neg Neg Pos 
87/24 U KPN KPC-19 Neg Pos Neg Pos 
MDR4547  ECO KPC -3 Neg Neg Neg Neg 
MDR4597  KPN KPC-19 Pos Neg Neg Neg 
MDR2114 ECO KPC-19 Neg Neg Pos Neg 
MDR2984 ECO KPC-19 Neg Neg Neg Neg 
MDR1958 KPN KPC-19 Neg Neg Neg Pos 
MDR2025 KPN KPC-19 Neg Neg Neg Pos 
 
 
 
Strain HI1 HI2 I1 X L/M N FIA FIB W Y P FIC A/C T FIIs FrepB K B 
N181 Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg 
87/24 U Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg 
MDR4547 Neg Neg Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg 
MDR4597 Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg 
MDR2114 Neg Neg Neg Neg Neg Pos Neg Pos Neg Neg Neg Neg Neg Neg Neg Pos Neg Neg 
MDR2984 Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg 
MDR1958 Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg 
MDR2025 Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg 
 
 
We performed blaKPC sequencing and plasmid characterization also for 8 
strains sharing similarities with discrepant ones but also showing the 11,109Da 
peak on their MALDI-TOF MS spectra, searching for a difference on gene or 
plasmids. All the strains showing the 11,109Da peak were positive for FIIs replicon, 
[Tab. 30] whereas the same replicon is negative for all discrepant strain, [Tab. 28] 
indicating the possibility of a different plasmid harboring blaKPC gene in these 
Tab. 27 KPC sequencing results and plasmid characterization [79] for discrepant strains: 
blaKPC positive, 11,109Da peak negative 
Tab. 28 Plasmid characterization [56] for discrepant strains: blaKPC positive, 11,109Da peak negative 
KPN, K. pneumoniae; ECO, E. coli; Pos, positive; Neg, negative 
Pos, positive; Neg, negative 
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strains and confirming the correlation between 11,109Da peak and plasmid, but not 
between the peak and blaKPC gene sequence. 
[73] [74] One strain (MDR53) harbored 
KPC-19, all the others had KPC-3. The results are summarized on Tab. 29 and 30. 
 
Strain Sequence IncQ IncR IncU OriColE 
N298 KPN KPC-3  Neg Neg Neg Pos 
MDR53 KPN KPC-19 Neg Neg Neg Pos 
MDR368 ECO KPC-3 Neg Neg Neg Neg 
MDR488 KPN KPC-3 Neg Neg Neg Pos 
MDR600  ECO KPC-3 Neg Neg Neg Neg 
MDR624  KPN KPC-3 Neg Neg Neg Pos 
MDR 1985 KPN KPC-3 Neg Neg Neg Pos 
MDR1696 ECO KPC-3 Neg Neg Neg Neg 
 
 
 
Strain HI1 HI2 I1 X L/M N FIA FIB W Y P FIC A/C T FIIs Frep
B 
K B 
N298 Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Pos Neg Neg Neg 
MDR53 Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Pos Neg Neg Neg 
MDR368 Neg Neg Neg Neg Neg Pos Pos Pos Neg Neg Neg Neg Neg Neg Pos Pos Neg Neg 
MDR488 Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Pos Neg Neg Neg 
MDR600 Neg Neg Neg Neg Neg Neg Pos Pos Neg Neg Neg Neg Neg Neg Pos Pos Neg Neg 
MDR624 Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Pos Neg Neg Neg 
MDR1985 Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Neg Pos Neg Neg Neg 
MDR2664 Neg Neg Neg Neg Neg Neg Neg Pos Neg Pos Neg Neg Neg Neg Pos Neg Neg Neg 
 
 
Tab. 29 KPC sequencing results and plasmid characterization [79] of 
selected strains: blaKPC positive, 11,109Da peak positive  
 
Tab. 30 Plasmid characterization [56] of selected strain: blaKPC positive, 11,109Da peak positive 
KPN, K. pneumoniae; ECO, E. coli; Pos, positive; Neg, negative 
Pos, positive; Neg, negative 
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For the 8 discrepant strains and the 8 control strains, we performed also 
PCRs for p019 and Tn4401 genes, to verify any correlation between p019 protein, 
transposon Tn4401 and presence of the 11,109Da peak in MALDI-TOF spectra. 
The results are presented in Tab. 31.  
 
Discrepant 
strains 
11,109Da 
peak 
p019 Tn4401 Control 
strains 
11,109Da 
peak 
p019 Tn4401 
N181 Absent Neg Neg N298 Present Pos Pos 
87/24 U Absent Neg Neg MDR53 Present Pos Neg 
MDR4547  Absent Neg Pos MDR368 Present Pos Pos 
MDR4597  Absent Neg Pos MDR488 Present Pos Neg 
MDR2114 Absent Neg Pos MDR600  Present Pos Neg 
MDR2984 Absent Neg Pos MDR624  Present Pos Neg 
MDR1958 Absent Neg Pos MDR 1985 Present Pos Neg 
MDR2025 Absent Neg Pos MDR1696 Present Pos Neg 
 
  
 PCR results showed a direct correlation between the 11,109Da peak and 
p019 gene. In fact, all discrepant strains, that is the strains having blaKPC gene, but 
missing the 11,109Da peak in MALDI-TOF spectra, are negative also for p019 
gene. Control strains, instead, that is strains having blaKPC gene, with the 11,109Da 
peak in MALDI-TOF spectra, are positive also for p019 gene. The correlation with 
Tn4401 gene, however, it is less clear because the gene codifying for transposon 
was detected in 6/8 of discrepant strains, but only in 2/8 control strains. [Tab. 31] 
 
 
 
 
 
Tab. 31 Results of PCRs for p019 and Tn4401 genes performed on 8 discrepant strains (KPC-
producing/missing 11,109Da peak) and 8 control strains (KPC-producing/with 11,109Da peak) 
 
Pos, positive; Neg, negative 
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PART II 
Spectra analysis for research of new peaks correlated with other 
carbapenemases: VIM and NDM 
 
Group 4 
 After having evaluated the effective correlation between KPC and MALDI-
TOF MS 11,109Da peak, we searched for other characteristic peaks correlated with 
VIM and NDM carbapenemases. For this purpose, we selected bacterial strains 
VIM and NDM producers and after having performed MALDI-TOF MS 
identification we analyzed their spectra. 
On 57 Enterobacteria strains from Croatia we performed Carba NP Test; 
MALDI-TOF MS identification; spectra analysis for the 11,109Da peak detection; 
PCRs for blaIMP/blaVIM/blaKPC and blaNDM genes.
 [78] 
From these 57 strains, we selected 23 strains with Carba NP test positive, 
negative for the 11,109Da peak and positive for blaVIM. [Tab. 32] The strains with 
Carba NP test negative were streaked 4 times on MH agar plates plus Imipenem 
(2mg/ml) and they were eliminated if the test confirmed negative.  
The MALDI-TOF MS spectra of these selected strains were used to create 
a superspectrum to individuate some or at least one protein common to all VIM 
producers, yet absent in the spectra of other samples not VIM producers. All strains 
were analyzed in duplicate and we used only spectra with a confidence ≥90% and 
with a minimum of 170 peaks, the others were repeated, because for this analysis 
the quality of spectra is extremely important, so as to have high number of peaks 
and to compare spectra that are similar for peaks number. 
We analyzed the spectra with Saramis software, creating an exclusion list 
to eliminate the proteins most represented (relative intensity from 50% to 80%) and 
common to other Enterobacteriaceae in the database. We produced a first list of 
170 proteins that we compared with the whole database to reduce further. Step by 
step, we reduced the list to 44 proteins, keeping those with a low relative intensity 
(10%), thus creating a VIM superspectrum. Then, we compared the superspectrum 
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with the database so as to eliminate the proteins common to Enterobacteriaceae 
susceptible to carbapenems. At the end, we found 7 proteins rare on the database, 
and performed the comparison mass vs spectra, we verified if one single protein 
could be correlated with VIM, but all were present also in other bacterial strains not 
VIM producers. 
The same analysis was performed for 13 P. aeruginosa strains selected from 
a collection of 61 strains, all with Carba NP test and blaVIM positive, [Tab. 33] but 
also in this case we found no specific peak correlated with VIM enzyme.  
 
 
Strain Carba Test  11,109Da peak blaVIM blaKPC blaIMP blaNDM 
1 ZAG K pneumoniae Pos Absent Pos Neg Neg Neg 
2 ZAG C freundii Pos Absent Pos Neg Neg Neg 
3 ZAG C freundii Pos Absent Pos Neg Neg Neg 
7 ZAG E cloacae Pos Absent Pos Neg Neg Neg 
8 ZAG E cloacae Pos Absent Pos Neg Neg Neg 
9 ZAG E cloacae Pos Absent Pos Neg Neg Neg 
10 ZAG E cloacae Pos Absent Pos Neg Neg Neg 
11 ZAG E cloacae Pos Absent Pos Neg Neg Neg 
12 ZAG C freundii Pos Absent Pos Neg Neg Neg 
13 ZAG E cloacae Pos Absent Pos Neg Neg Neg 
26 ZAG E cloacae Pos Absent Pos Neg Neg Neg 
27 ZAG K oxytoca Pos Absent Pos Neg Neg Neg 
28 ZAG E cloacae Pos Absent Pos Neg Neg Neg 
30 ZAG E cloacae Pos Absent Pos Neg Neg Neg 
31 ZAG E cloacae Pos Absent Pos Neg Neg Neg 
32 ZAG E cloacae Pos Absent Pos Neg Neg Neg 
33 ZAG E cloacae Pos Absent Pos Neg Neg Neg 
34 ZAG Enterobacter sp. Pos Absent Pos Neg Neg Neg 
40 ZAG C freundii Pos Absent Pos Neg Neg Neg 
44 ZAG C freundii Pos Absent Pos Neg Neg Neg 
53 ZAG K pneumoniae Pos Absent Pos Neg Neg Neg 
57 ZAG K oxytoca Pos Absent Pos Neg Neg Neg 
61 ZAG C freundii Pos Absent Pos Neg Neg Neg 
Tab. 32 VIM-producing Enterobacteriaceae strains selected to create a superspectrum to 
search a characteristic peak VIM related 
Pos, positive; Neg, negative 
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Strain Carba 
NP Test  
blaVIM blaKPC blaIMP 
PSE BG P. aeruginosa Pos Pos Neg Neg 
Pae 390 P. aeruginosa Pos Pos Neg Neg 
PSE4 P. aeruginosa Pos Pos Neg Neg 
PSE B P. aeruginosa Pos Pos Neg Neg 
PSE F P. aeruginosa Pos Pos Neg Neg 
PSE P P. aeruginosa Pos Pos Neg Neg 
2523 P. aeruginosa Pos Pos Neg Neg 
2553 P. aeruginosa Pos Pos Neg Neg 
2609 P. aeruginosa Pos Pos Neg Neg 
2622 P. aeruginosa Pos Pos Neg Neg 
2677 P. aeruginosa Pos Pos Neg Neg 
2678 P. aeruginosa Pos Pos Neg Neg 
2682 P. aeruginosa Pos Pos Neg Neg 
 
 
 
We performed also a conjugation between 1 K. oxytoca and 1 C. freundii 
strains both VIM-producing as donors and E. coli J53 as recipient, so as to compare 
the spectrum of J53 and that of J53 transconjugant, to individuate a possible peak 
present only on the transconjugant, but the conjugation failed.  
 
 
In the same way, we searched for a peak NDM correlated, using the spectra 
of 15 selected NDM-producing Enterobacteria strains from Croatia, positive for 
Carba NP test and blaNDM and negative for 11,109Da peak. [Tab. 34]  
 
 
 
 
 
 
Tab. 33 VIM-producing P. aeruginosa strains selected to create a 
superspectrum to search a characteristic peak VIM correlated  
Pos, positive; Neg, negative 
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Strain Carba 
NP Test  
11,109Da 
peak 
blaNDM 
HR40/E C. koseri Pos Absent Pos 
HR85/E K. Pneumoniae Pos Absent Pos 
HR88/E K. Pneumoniae Pos Absent Pos 
HR107/E K. Pneumoniae Pos Absent Pos 
HR112/E K. Pneumoniae Pos Absent Pos 
HR113/E K. Pneumoniae Pos Absent Pos 
HR117/E K. Pneumoniae Pos Absent Pos 
HR324/E K. Pneumoniae Pos Absent Pos 
5 ZAG C. freundii Doub Absent Pos 
29 ZAG K. Pneumoniae Pos Absent Pos 
60 ZAG E. cloacae Neg Absent Pos 
66 ZAG E. cloacae Neg Absent Pos 
H85 transconj E. coli Pos Absent Pos 
H88 transconj E. coli Pos Absent Pos  
H113 transconj E. coli Pos Absent Pos 
 
 
 
The spectra of these strains were used to create a NDM superspectrum, but 
also for NDM we did not find any characteristic peak. Also, comparison of E. coli 
J53 spectrum and transconjugant spectra did not reach a result, not even performing 
MALDI-TOF analysis for plasmid of strain HR107 harboring blaNDM gene. 
[97]  
 
After the first spectra analysis, we characterized the plasmids of the VIM- 
and NDM-producing Enterobacteria strains and divided the samples in groups 
based on the different plasmid type harbored (L/M, A/C, IncR, OriColE), then we 
repeated the spectra analyses in each group, but also in this way we not found a 
peak correlated with enzymes. [Tab. 35-36]                                 
                         
         
Tab. 34 NDM-producing Enterobacteria strains selected to create a 
superspectrum to search a characteristic peak NDM related  
Pos, positive; Neg, negative; Doub, doubtful 
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 1 ZAG   L/M      7 ZAG A/C    
2 ZAG  L/M  IncR   ColE 8 ZAG A/C    
3 ZAG  L/M  IncR   ColE 9 ZAG A/C    
12 ZAG  L/M  IncR   ColE 10 ZAG A/C  IncN  
33 ZAG  L/M      11 ZAG A/C    
40 ZAG  L/M  IncR  IncP ColE 13 ZAG A/C    
44 ZAG  L/M  IncR   ColE 26 ZAG A/C    
53 ZAG  L/M A/C  IncN   28 ZAG A/C IncQ  ColE 
61 ZAG  L/M      30 ZAG A/C    
        31 ZAG A/C   ColE 
57 ZAG       ColE 32 ZAG A/C    
        34 ZAG A/C    
                                               
 
 
 
HR40/E  IncR    HR112/E A/C FIA ColE  
HR85/E  IncR    HR117/E A/C  ColE  
HR88/E  IncR    5 ZAG A/C    
HR107/E  IncR    29 ZAG A/C   H1 
HR324/E  IncR  ColE L/M 60 ZAG A/C  ColE  
      66 ZAG A/C  ColE  
      HR113/E   ColE  
           
  
 
 
 
 
 
 
Tab. 35 VIM-producing Enterobacteria strains arranged by classes according to their plasmid 
characterization [56] [79]  
Tab. 36 NDM-producing Enterobacteria strains arranged by classes according to their plasmid 
characterization [56] [79] 
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PART III 
To evaluate the use of MALDI-TOF MS system to quickly detect hospital 
outbreaks 
 
Group 5 
Fourty-four K. pneumoniae strains from a frozen collection, isolated from 
23 patients during an outbreak onset in ICU of our hospital, from January to March 
2015, were used to evaluate the utility of MALDI-TOF MS system to quickly detect 
clonal correlation. 
For all strains, we performed Carba NP test and PCRs for 
blaIMP/blaVIM/blaKPC genes,
 [78] to confirm carbapenemase production. MALDI-
TOF MS spectra analysis was used to detect the 11,109Da peak and to find genetic 
correlation; also, PFGE was performed because it is the Gold Standard for strains 
typing. [98] [99] 
The results of Carba NP test, PCR and MALDI-TOF MS for detection of 
the 11,109Da peak are summarized in Tab. 37. 
 
Strain Carba 
NP Test  
blaKPC blaVIM blaIMP 11,109Da 
peak 
Date sample 
collected 
Patient 
MDR1689 Pos Pos Neg Neg 11,109 08/01/2015 1 
MDR1690 Pos Pos Neg Neg 11,111 08/01/2015 1 
MDR1692 Pos Pos Neg Neg 11,107 08/01/2015 2 
MDR1693 Pos Pos Neg Neg 11,107 08/01/2015 2 
MDR1695 Pos Pos Neg Neg 11,110 08/01/2015 4 
MDR1728 Pos Pos Neg Neg 11,110 15/01/2015 1 
MDR1730 Pos Pos Neg Neg 11,111 15/01/2015 1 
MDR1731 Pos Pos Neg Neg 11,109 15/01/2015 5 
MDR1732 Pos Pos Neg Neg 11,109 15/01/2015 5 
MDR1741 Pos Pos Neg Neg 11,111 17/01/2015 6 
MDR1761 Pos Pos Neg Neg 11,109 22/01/2015 1 
MDR1762 Pos Pos Neg Neg 11,111 22/01/2015 7 
MDR1764 Pos Pos Neg Neg 11,110 22/01/2015 7 
Tab. 37 K. pneumoniae strains from collection, isolated from 23 patients during an epidemic episode in ICU in 2015 
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MDR1765 Pos Pos Neg Neg 11,110 22/01/2015 1 
MDR1771 Pos Pos Neg Neg 11,108 24/01/2015 8 
MDR1794 Pos Pos Neg Neg 11,110 29/01/2015 1 
MDR1796 Pos Pos Neg Neg 11,107 29/01/2015 7 
MDR1821 Pos Pos Neg Neg 11,106 03/02/2015 9 
MDR1822 Pos Pos Neg Neg 11,110 03/02/2015 9 
MDR1835 Pos Pos Neg Neg 11,110 05/02/2015 10 
MDR1836 Pos Pos Neg Neg 11,108 05/02/2015 7 
MDR1868 Pos Pos Neg Neg 11,110 11/02/2015 11 
MDR1870 Pos Pos Neg Neg 11,109 12/02/2015 7 
MDR1874 Pos Pos Neg Neg 11,110 12/02/2015 7 
MDR1914 Pos Pos Neg Neg 11,111 19/02/2015 12 
MDR1916 Pos Pos Neg Neg 11,108 19/02/2015 10 
MDR1917 Pos Pos Neg Neg 11,110 19/02/2015 13 
MDR1919 Pos Pos Neg Neg 11,110 19/02/2015 14 
MDR1924 Pos Pos Neg Neg 11,112 19/02/2015 15 
MDR1953 Pos Pos Neg Neg 11,110 27/02/2015 12 
MDR1955 Pos Pos Neg Neg 11,111 27/02/2015 1 
MDR1958 Pos Pos Neg Neg  Absent 28/02/2015 16 
MDR1981 Pos Pos Neg Neg 11,107 05/03/2015 17 
MDR1985 Pos Pos Neg Neg 11,106 05/03/2015 18 
MDR2015 Pos Pos Neg Neg 11,114 12/03/2015 1 
MDR2016 Pos Pos Neg Neg 11,106 12/03/2015 19 
MDR2018 Pos Pos Neg Neg 11,105 12/03/2015 20 
MDR2019 Pos Pos Neg Neg 11,112 12/03/2015 21 
MDR2024 Pos Pos Neg Neg 11,105 13/03/2015 18 
MDR2025 Pos Pos Neg Neg Absent 13/03/2015 16 
MDR2027 Neg Neg Neg Neg Absent 13/03/2015 17 
MDR2048 Pos Pos Neg Neg 11,108 19/03/2015 22 
MDR2081 Pos Pos Neg Neg 11,108 26/03/2015 23 
MDR2085 Pos Pos Neg Neg 11,107 26/03/2015 24 
        
 
 
 
 
Pos, positive; Neg, negative 
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Forty-three out of forty-four strains were positive for Carba NP test and 
positive also for blaKPC. [Tab. 37] 
One strain (number 2027, from patient 17) resulted negative at Carba NP 
test, PCR for bla genes and MALDI-TOF 11,109Da peak detection. [Tab. 37] 
After MALDI-TOF analysis, we found 2 discrepant strains (number 1958 
and 2025 from patient 16), that is strains that carried blaKPC gene, without the 
11,109Da peak in their MALDI-TOF spectra. These strains were retested twice by 
MALDI-TOF MS system, before and after using MH plates additioned with 
Imipenem (2 µg/ml), and we performed sequencing blaKPC gene, plasmid extraction 
and characterization. [56] [79] [Tab. 27 and 28] 
 After identification, the MALDI-TOF MS spectra of all 44 strains, including 
the susceptible ones, were imported in Saramis database to perform the clustering 
analysis. The software showed the relative taxonomy creating a dendrogram based 
on mass similarity, with tolerance (%): 0.08; Absolute intensity ≥0; Relative 
intensity ≥0. [Fig. 40] 
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Fig. 40 Dendrogram obtained through MALDI-TOF MS spectra of 44 K. pneumoniae strains isolated during an 
outbreak in our hospital. The strains marked in red and blue are also shown in PFGE fingerprint in Fig. 41 and 
PFGE dendrogram in Fig. 42. The strains marked in pink and green are also shown in PFGE fingerprint in Fig. 43 
and PFGE dendrogram in Fig. 42. The strains marked with an arrow have 100% similarity two by two. They are 
also shown in Fig. 42-43-44.                        
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For the same strains, PFGE was performed, obtaining a fingerprint after 
XbaI digestion, examples illustrated in Fig. 41, 43 and 44. The results of restriction 
patterns were analyzed by FPQuest™ Software. Band similarity analysis was 
performed by Dice coefficients (SD) [96] [98], with position tolerance of 1.5%, on the 
basis of the unweighted average pair group method (UPGMA), [100] obtaining the 
dendrogram shown in Fig. 42. 
 
 
 
 
 
 
 
 M    1868  1870  1874  1762  1764  1796  1836  1914 
Fig. 41 PFGE fingerprint of 8 K. pneumoniae strains out of 44 isolated 
in ICU during an epidemic onset. Strains 1868 to 1796 and strain 1914 
are the same as in Fig. 40 and Fig. 42 where they are marked in red. 
Strain 1836 is the same as in Fig. 40 and Fig. 42, marked in blue. 
M=marker. 
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 The fingerprint in Fig. 41 shows 7 strains with similar PFGE pattern (strains 
from 1868 to 1796, and strain 1914), and strain 1836 with a different PFGE pattern. 
Strains 1870, 1874, 1764, 1762, 1796 and 1836 were isolated from samples of a 
same patient (number 7). Instead, strain 1914 was isolated from patient 12 and strain 
1868 from patient 11.  
 The strains 1762 and 1764 were isolated first, on the 22nd of January 2015, 
strain 1796 on the 29th of January and the others in February 2015, i.e. strain 1836 
Fig. 42 Results of PFGE on 44 K. pneumoniae strains isolated during an outbreak in our hospital, analyzed with 
FPQuest™ Software. The strains marked in red and in blue are the same as shown in MALDI-TOF dendrogram 
Fig. 40 and PFGE fingerprint in Fig. 41. The strains marked in pink and in green are the same as shown in Fig. 40 
and 43. The strains marked with an arrow have 100% similarity two by two. They are also shown in Fig. 40-43-44.                                       
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on the 5th, strains 1870 and 1874, on the 12th and finally, strain 1914 on the 19th.  
[Tab. 37] 
 These 8 bacterial strains present dissimilar results regarding MALDI-TOF 
MS comparison and PFGE. 
 In MALDI-TOF MS dendrogram, these strains all present a percentual 
similarity between ~69 and ~85%. None of them show similarity higher than 85%. 
Strain 1836 clearly different in terms of PFGE fingerprint, has a similarity of about 
~75% in MALDI-TOF MS dendrogram. [Fig 40]  
The PFGE, instead, shows that strains 1870 and 1874 have percent 
similarity 97.6%. Strain 1764 has similarity 93.8% with the first two. Strains 1762 
and 1796 have 95% similarity, and 89.3% similarity with the previous ones. These 
five strains were isolated from the same patient. Strain 1914 has 86.8% similarity 
with the previous ones, and strain 1868 has 83.7% similarity with the previous ones. 
These last two strains were isolated from patients 12 and 11 respectively. Finally, 
strain 1836 has 47.4% similarity with all the other strains. 
According to PFGE analysis, 5 strains (1868, 1762, 1764, 1796, 1914) are 
closely related to each other, because they have a percent similarity >81%. Two 
strains (1870, 1874) are identical, as they have percent similarity >97%. [98] The last 
strain, instead, with 47.4% similarity is not related to the others. [Fig. 42] [Tab. 38] 
The results of the MALDI-TOF MS analysis, on the other hand, is not as clear, 
because the 7 strains (cluster at PFGE) are distributed on the dendrogram, and it 
would seem they had close relation with other strains but not to each other. Strain 
1836, instead, not related to other strains according to PFGE, in MALDI-TOF MS 
relative taxonomy has ~75-78% similarity with strain 1796, 1761 and others. [Fig. 
40] [Tab.38] 
Another example of different interpretation of dendrogram results on PFGE 
and MALDI-TOF MS, are the two strains (1958 and 2025) resulted discrepant at 
MALDI-TOF MS spectra analysis for the 11,109Da peak detection. Both were 
isolated from patient 16 with a gap of two weeks between them. [Tab. 37] The 
PFGE fingerprint [Fig. 43] and the PFGE dendrogram show they are closely related, 
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with 90.9% similarity, and they differ from the other strains (73% and 68.5% 
similarity with two cluster). [Fig. 42] Curiously, in MALDI-TOF dendrogram, each 
of them is related to strains collected from other patients, but not to each other. [Fig. 
40]      
In Fig. 43 strain 2027 is also shown, the only one resulting negative for 
carbapenemase production in this group of strains. It was isolated from patient 17 
in March 2015, after the isolation of another strain positive for blaKPC (1981), one 
week earlier. According to the PFGE dendrogram, it seems clear that this strain is 
unrelated to the other strains, as it shows 40.4% similarity with them. [Fig. 42] In 
MALDI-TOF dendrogram, instead, the strain has over 70% similarity with other 
strains. [Fig. 40] 
 
 
 
 
 
 Also, according to PFGE fingerprint there are 6 strains that have 100% 
similarity with each other: strains 2018 and 2019 (patient number 20 and 21); strains 
1916 and 1835 (both patient 10); and finally strains 1690 and 1765 (both patient 1). 
[Fig. 42-43-44]   
 M    1689  1690   1728   1765    1761   1794    1730   1958    2025    1981    2027    1985   2024    2016   2018    2019 
Fig. 43 PFGE fingerprint of 16 K. pneumoniae strains out of 44 isolated during an epidemic onset. Strains 1958 and 
2025 are discrepant for PCR and the 11,109Da peak detection.  In Fig. 40 and 42 are marked in pink. Strain 2027 
results negative at Carba NP test, PCR for bla genes and 11,109Da peak detection. It is the same as in Fig. 40 and 42 
marked in green. At PFGE strains 1690 and 1765 are identical, strains 2018 and 2019 are identical. They are shown 
also in Fig. 40 and 42. M=marker.                                  
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 Also in this case, there is no accordance between PFGE and MALDI-TOF 
results. Only the strains 2018 and 2019, in fact, have about 80% of similarity, the 
others are not closely related in the MALDI-TOF taxonomy. [Fig. 40]                   
 
 
 
 
 
 
 Finally, according to PFGE fingerprint, 2 strains isolated from pharyngeal 
and rectal swab from patient number 5 (strain 1731 and 1732) result almost identical 
to each other (97% similarity), but not related with the other strains (33% 
similarity). [Fig. 42] [Fig. 45] The MALDI-TOF MS dendrogram does not show 
the same result. Strain 1732 has about 70% similarity with strain 1689, but it is not 
closely related to strain 1731, which in turn has ~75% similarity with strain 1765. 
[Fig. 40]  
 M    1953  1916  1835  1924  1917  1919  1955 2015 
Fig. 44 PFGE fingerprint of 8 K. pneumoniae strains out of 44 isolated 
during an epidemic onset. Strains 1916 and 1835 are identical. They are 
shown also in Fig. 40 and 42. M=marker. 
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  Tab. 36 synthetizes the results of PFGE and MALDI-TOF MS relative 
taxonomy of the strains already presented in Fig. 40 to Fig. 45. 
 
 
 
 
 
 
 
 
 
 M   1693  1694  1695  1731   1732  1741   1771  1821  1822 
Fig. 45 PFGE fingerprint of 8 K. pneumoniae strains out of 44 isolated during 
an epidemic onset. Strains 1731 and 1732 isolated from pharyngeal and 
rectal swab from patient 5 are identical and differ from all the other strains. 
They are shown also in Fig. 40 and 42. M=marker. 
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 After observing the difference between PFGE and MALDI-TOF MS 
relative taxonomy, we have decided to verify whether this diversity was due to the 
Strain Patient PFGE 
Percent similarity 
MALDI-TOF MS 
Percent similarity 
1870 7 
97.6% 
93.8% 
89.3% 
86.8% 
83.7% 
Relationship not clear 
 
Similarity between 69% 
and 85% 
1874 7 
1764 7  
1762 7 
95% 
 
1796 7  
1914 12    
1868 11     
1836 7 47.4% Not related 
with the 7 strains above 
1958        16 
90.9%  Related with other 
strains. Not closely 
related to each other  
2025   16 
2027 17 Not related with any other 
51.6% only with one strain 
~ 71% similarity with 
other strains 
2018     20 
100% 
    
~ 80% 
2019 21     
1916     10 
100% 
    
Relationship not clear 
1835 10     
1690 1 
100% 
    
Relationship not clear 
1765 1     
1731 5 
97% 33% with other strain 
 
Not closely related each 
other. Related with 
other strains  
1732 5 
Tab. 38 Results of the comparison between PFGE and MALDI-TOF MS relative taxonomy, concerning the strains 
already presented in Tab. 41 to Tab. 46. Cut-off for similarity between strains was 81% for type (closely related) 
and 97% for subtype (identical) [98] 
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number of our samples. Therefore, we selected the spectra of the strains which at 
PFGE fingerprint clearly formed a cluster, then revaluating the MALDI-TOF MS 
relative taxonomy in each group. [Fig. 46] [Fig. 47] 
 For example, the 7 strains mentioned above (1868, 1870, 1874, 1762, 1764, 
1796 and 1914) as well as strains 1771 and 1981, which resulted a cluster at PFGE, 
if evaluated separately for MALDI-TOF MS relative taxonomy, they show different 
percentages of similarity, ranging from ~68% to ~78%, but still different from those 
of PFGE. [Fig. 46]  
                      
 
  
 We also repeated the evaluation of the relative taxonomy at MALDI-TOF 
MS for 17 strains, including some already presented in Tab. 38 (namely strain 1958, 
2025, 1916, 1835, 1690, 1765). Again, strains with 100% similarity in groups of 
two by two at PFGE (strains 1916 and 1835; strains 1690 and 1765) were not 
closely related at MALDI-TOF MS evaluation. Also strains 2025 and 1958 were 
identical to each other, but different from the other ones according to PFGE 
fingerprint, yet they do not have the same similarity at MALDI-TOF MS evaluation 
(<80% similarity).  
Fig. 46 MALDI-TOF MS relative taxonomy (on the left) repeated for a group of 9 strains that resulted 
a cluster at PFGE (strains marked on the right). 
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 Finally, also revaluating these 17 strains with the 4 strains already presented 
in Tab. 37 (namely strain 1836, 2027, 1731 and 1732), resulting clearly not related 
with the others at PFGE, the difference between PFGE and MALDI-TOF MS 
evaluation remains confirmed. [Fig. 48] 
    
   
 
Fig. 47 MALDI-TOF MS relative taxonomy (on the left) repeated for a group of 17 strains 
distributed in 4 cluster at PFGE (on the right). The strains marked (1690 and 1765) are identical 
according to PFGE (100% similarity) but not even closely related for MALDI-TOF MS evaluation. 
Fig. 48 Repeated MALDI-TOF MS relative taxonomy (on the left) of a group of 17 strains (previously 
presented in Fig. 47) forming four clusters according to PFGE, with 4 strains resulting clearly not 
related (on the right). The strains marked (1731 and 1732) are identical according to PFGE (97% 
similarity) but not closely related at MALDI-TOF MS evaluation. Strains 2027 and 1836 are not related 
with anyone at PFGE, but at MALDI-TOF MS relative taxonomy they presented ~72% and ~75% 
similarity with other strains. 
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 Strains 1731 and 1732, in fact, which have 97% similarity at PFGE, on 
MALDI-TOF MS relative taxonomy are not even closely related (strain 1732 has 
70% similarity with strain 1689 and <70% with a group of strains including strain 
1731). Strain 2027 clearly not related to any other at PFGE (40.4% similarity), at 
MALDI-TOF MS has ~72% similarity with strain 1953 and other ones. Strain 1836 
which at PFGE has 40.4% similarity with other strains, at MALDI-TOF MS relative 
taxonomy it has ~75% similarity with strain 1761 and some more. [Fig. 48] 
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DISCUSSION AND CONCLUSION                   
 
Antibiotic resistance is a widespread phenomenon, recognized by 
International Health Organizations as a new global public health crisis. [7] [22] 
Carbapenem-resistant Enterobacteriaceae especially represent a major concern 
mostly in hospital settings, since they spread very quickly. The problem is clinical, 
with severe illness, frequent epidemic outbreaks in hospitals and rate of mortality 
that reach 50-80%, but economic also, for prolonged hospitalization and treatments, 
for the use of expensive drugs and increasing demand of screening tests. 
ECDC estimate that each year, about 25,000 patients die in Europe, from an 
infection with multidrug-resistant bacteria. These infections count for an extra 2.5 
million hospital days, with an economic burden estimated to be at least EUR1.5 
billion in Europe in 2007. [9] [25] 
 In Italy, resistance percentages have had an increasing trend during the last 
years, among the highest in Europe, especially for Gram-negative bacteria. For 
example, percentage of isolates of carbapenem-resistant K. pneumoniae arose from 
1% in 2006 to 33% in 2014. [26] [29] [Tab. 4]        
In Verona, too, we observed a general increase of resistant strains isolated 
in our hospital. For example, carbapenem-resistant K. pneumoniae strains isolated 
in our clinical lab, were 1.94% in 2009, and arose to 61.76% in 2011. However, 
after the beginning of the screening program in 2013, we observed a slight decrease 
(39.2% in 2015). [Graph. 1] Screening, thus, proves itself to be an important 
strategy to reduce resistance rate, because it helps contain the transmission of 
resistant-strains in those cases in which resistance is plasmid-mediated, and 
therefore easily spread. 
At the moment, available diagnostic assays are countless, ranging from 
traditional culture-based methods to more recent genetic and proteomic ones. They 
are highly sensitive and specific, but often time-consuming, some are very 
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expensive and hard to perform and require specific instruments and expertise. Thus, 
they are not feasible in clinical laboratories, but only in reference laboratories.  
As a consequence, it is a priority for researchers to provide new diagnostic 
tools for clinical labs, more suited for their needs so that they can respond to an 
increasing number of requests from clinicians, giving them accurate results which 
also save time and money.   
The main necessity is to quickly identify carbapenemase-producing 
bacterial strains in infected and colonized patients, in order to efficiently contain 
the spreading and assess proper therapy. Carbapenem-resistant Enterobacteriaceae, 
in fact, have been classified by CDC at hazard level “urgent”, as they cause 
hospital-acquired infections, which leave very limited therapeutic options and 
consequently bring high mortality rates. [7]  
The routine screening for multidrug-resistant strains (MDR) in our clinical 
laboratory, performed on rectal swabs, is based on traditional overnight culture. The 
time required to report was reduced from the 72 hours needed with traditional 
identification, susceptibility tests and confirmatory tests, to 24 hours only, with the 
use of selective chromogenic agar plates (ChomID ESBL agar) with ertapenem 
disk, rapid phenotypic Carba NP test [68] (results in 2 hours) and MALDI-TOF 
identification (results in a few minutes). Also, costs were reduced (about EUR5 per 
screening including the costs for detection of several types of multi-resistant strains, 
not only of carbapenemase-producers). Molecular technics such as Real-Time PCR 
could reduce the detection time even further starting directly from samples, but their 
costs are not always compatible with the high number of samples tested in a hospital 
clinical laboratory (about EUR30-50 for each single screening).  
Mass-Spectrometry-based method MALDI-TOF, represents an innovative 
system for bacteriology, is currently used in diagnostics to identify bacterial 
species, but could be implemented as a new tool to quickly detect resistant strains 
with high sensitivity, and with a significant decrease in time and costs. This would 
be especially useful for laboratories, like our clinical Microbiology lab, that 
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provides a service for a medium/big hospital, with high and increasing number of 
MDR screening requests (about 12,000 tested samples last year).  
Numerous studies have demonstrated the possible use of MALDI-TOF MS 
to recognize resistant and susceptible strains. At the moment, most of the published 
data concerns the detection of carbapenemase activity measuring antibiotic 
hydrolysis. [71] [101] Few studies instead, were performed in order to use MALDI-
TOF MS spectra acquired during the ordinary identification to detect resistance 
determinants, based on the presence/absence of a specific peak. [73] [74] [102] [103] There 
are, moreover, very few data about clinical application and utility [74] [102] and all 
studies were performed only by one of two MALDI-TOF systems applied to 
microbiology, namely that patented by Bruker Daltonics, whereas we have 
employed the other system for microbiology patented by bioMérieux, which makes 
use of the same technology, but with a different software (Shimadzu Launchpad) 
and different database (SARAMISTM Premium (Spectral ARchivee And Microbial 
Identification System) ID-professional (AnagnosTec-bioMérieux)). In addition, the 
use of MALDI-TOF for typing, compared with PFGE, was also evaluated from 
many research groups, but again these studies were performed using Bruker 
Daltonics system. [76] [77] 
 
The initial aim of this study, started in January 2014, was to look for a peak 
in MALDI-TOF spectra, which could be used as marker for rapid detection of 
carbapenemase production, especially for KPC. During our research, we found a 
study based on 18 outbreak isolates published by Lau and coll., [73] who had already 
identified a MALDI-TOF peak (11,109Da) corresponding to pKpQIL plasmid, 
harboring KPC gene, and proposed it as marker for this plasmid and consequently 
for KPC detection. [73] Therefore, we have continued our experiments to confirm 
our theory and the published study on a wider range of samples, and verify if it 
would also apply to our specific context, using a different MALDI-TOF system. 
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Our purpose was indeed, to evaluate the ability of MALDI-TOF MS system 
used in our clinical laboratory to detect antimicrobial resistance mechanisms and to 
validate the use of this peak detection to quickly spot carbapenemase-producing 
Enterobacteriaceae, through the spectra already acquired during species 
identification, in order to improve the analytical capability of our lab.  
The main goal was reached through three specific objectives that represent 
the three sections of this work, performed in close collaboration with our clinical 
Microbiology laboratory. 
Part I - To confirm the correlation between KPC production and a 
characteristic MALDI-TOF MS spectrum with 11,109Da peak detected in 2014 by 
Lau and coll. [73] We also wanted to demonstrate the usefulness of 11,109Da peak 
detection in diagnostic workflow for rapid screening of KPC-producing 
Enterobacteria. 
Part II - To eventually detect new characteristic MALDI-TOF MS peaks for 
carbapenemase other than KPC: NDM and VIM. 
Part III - To evaluate the use of MALDI-TOF MS system during hospital 
outbreaks to identify bacterial strains clonally related. 
The study included Enterobacteriaceae strains isolated in clinical samples 
collected during MDR screening in Microbiology Laboratory of Verona Hospital 
and Negrar Hospital (Verona). We identified the bacterial strains with MALDI-
TOF MS system, evaluated the antibiotic susceptibility with systems in use in our 
laboratories and detected and confirmed carbapenemase production. We correlated 
also the results of MALDI-TOF MS measurements with phenotypic and genetic 
data to obtain an epidemiologic and molecular analysis of the diffusion pattern of 
multidrug-resistant Enterobacteria in Verona geographic area. 
 In the first part of the study, we confirmed that 11,109Da peak in MALDI-
TOF MS spectra is correlated with KPC production and later, we demonstrated how 
to use this correlation in ordinary diagnostic workflow. 
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In a first step, 436 Enterobacteria strains (Group 1) were used to investigate 
the correlation between the presence of the 11,109Da peak in MALDI-TOF MS 
spectra and KPC-production. We acquired and analyzed the MALDI-TOF MS 
spectra of 176 well-characterized KPC-producing strains (K. pneumoniae and E. 
coli) and 58 well-characterized ESBL-producing and carbapenem-resistant, but not 
carbapenemase producer strains (K. pneumoniae and E. coli). As control group, we 
analyzed the spectra of 27 β-lactam-susceptible K. pneumoniae, 121 ESBL-
producing E. coli, 15 NDM-producing and 39 VIM-producing Enterobacteria 
strains from collection. [Fig. 25] The 11,109Da (±8) peak was present in 99.4% 
(175/176) of the spectra of KPC-producing strains. In all 260 strains negative for 
KPC the peak was absent. Only one strain, therefore considered discrepant, was 
positive for KPC production, confirmed by bla genes PCR, without 11,109Da peak 
in MALDI-TOF MS spectra. [Tab. 23 and 24] 
Afterwards, we also analyzed two other groups of strains by collection: 11 
E. coli all KPC producers (Group 3) [Fig. 27] and 44 K. pneumoniae (43 KPC 
producers and 1 negative for carbapenemase production) (Group 5). [Fig. 29] By 
MALDI-TOF spectra analysis, we found 2 discrepant strains in each group. [Tab. 
27 and 28] Therefore, totally the 11,109Da peak by spectra analysis was observed 
in 97.8% (225/230) of KPC-producing strains. On the other hand, none of 261 
strains carbapenem-susceptible, carbapenemase-producing other than KPC (VIM 
or NDM) or carbapenem-resistant but not carbapenemase producers, as well ESBL-
producing strains, had the same peak.  
Thus, we demonstrated there is indeed a strong correlation between 
MALDI-TOF MS 11,109Da peak and KPC production, confirmed by PCR. 
Sensitivity in fact, is 97.8% and specificity 100%, with Positive Predictive Value 
100% and Negative Predictive Value 98%. These results were encouraging and lead 
us into evaluating a possible applicability of spectra analysis to routine screening.  
 In the second step, thus, we demonstrated that the analysis of MALDI-TOF 
MS spectra to detect the 11,109Da peak can be used not only in research laboratory, 
but also for MDR rapid screening in clinical laboratory, and demonstrate many 
practical advantage of this method for diagnostic routine. 
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The reliability of the method was verified by searching for this specific peak 
during routine workflow in our clinical microbiology lab. Rectal and at times 
pharyngeal swabs were processed by three different technicians according to 
protocols in use. From May to July 2016, we examined daily, the MALDI-TOF MS 
spectra obtained during bacterial species identification. We limited the 
investigation to strains identified as possible carbapenem-resistant, by isolation on 
ESBL ChromID agar plate, showing an inhibition zone diameter with ertapenem 
disk <22 mm and with positive Carba NP test. The same way, we investigated as 
control group some strains isolated in the same context, showing zone diameter for 
ertapenem disk >22 mm, with negative Carba NP test and positive ESBL NDP test. 
(Group 2) [Fig. 26] 
Totally, we analyzed 183 spectra, 135 of strains with positive Carba NP test 
(124 K. pneumoniae, 8 E. coli, 3 Enterobacter sp.) and 48 strains with negative 
Carba NP test and positive ESBL NDP test. (47 K. pneumoniae, 1 E. coli). It results 
that 129 out of 135 MALDI-TOF MS spectra of the strains with Carba test positive 
had also the 11,109Da peak. None of the spectra of the 48 strains with Carba NP 
test negative had the 11,109Da peak. [Tab. 25] Spectra analysis for detection of the 
11,109Da peak, in this group of strains had 95.5% sensitivity (129/135) and 100% 
specificity (48/48). 
  Analysing the discrepant strains, however, we found 3 strains producing 
carbapenemases other than KPC, namely 1 E. coli NDM producer, and 1 E. 
aerogenes and 1 E. cloacae, VIM producers. We concluded, therefore, that the real 
discrepants were 3 only, namely 2 K. pneumoniae and 1 E. coli, and so sensitivity 
arose to 97.7% (129/132) and specificity confirmed 100% (51/51). Thus, Positive 
Predictive Value (PPV) was 100% and Negative Predictive Value (NPV) is 94.4%. 
Analysis of discordant strains was performed to clarify the absence of the 
peak.                     
Totally, discrepant strains were 8/362 KPC-producing strains, namely 3 E. 
coli and 5 K. pneumoniae.  All were confirmed KPC producers based on PCR for 
blaKPC and confirmed expressing the gene, based on Carba NP test positive, yet 
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without the 11,109Da peak in MALDI-TOF MS spectra. We looked for any 
common characteristic amongst the strains that could possibly justify the 
discordance, to try to understand if it could interfere with the usage proposed.  
By sequencing the blaKPC gene we concluded that 2 were KPC-3 and the 
others were KPC-19. The resistance plasmids harboring the KPC gene were 
investigated through PBRT protocol of Carattoli et al. [56] [79] and showed scaffolds 
that resulted different. Three strains harbored plasmid replicon OriColE; 1 carried 
IncR and OriColE; 1 carried FIA and FIB; 1 IncQ; 1 IncN, FIB and FrepB; 1 strain 
none at all. [Tab. 27 and 28]  
As control group, we selected 8 not discrepant strains, namely 3 E. coli and 
5 K. pneumoniae. All these strains were KPC producers and had the 11,109Da peak 
in their MALDI-TOF spectra. We performed blaKPC sequencing and plasmid typing 
for these strains too. Only one strain resulted harboring KPC-19, the others carried 
all KPC-3. [Tab. 29 and 30] These strains showed different replicons, according 
plasmid characterization, [56] [79] and the element that appeared common and yet 
different from discordant strains was the presence of FIIs replicon in these, but not 
in the discrepant ones. [Tab. 28 and 30] The FIIs rep is the replicon most frequently 
present in plasmid pKpQIL, carrying transposon Tn4401, very common in KPC-
producing strains.  
Finally, for all 8 discrepant strains and 8 control strains we performed PCRs 
to detect p019 and Tn4401 genes. The results were that only control strains (positive 
for 11,109Da peak and IncFII plasmid) contained p019 gene. The distribution of 
Tn4401 gene, instead, is not the same in discrepant and control group (6 positive 
and 2 positive respectively). [Tab. 31] 
 
Our results, thus, when analysing both selected strains and random strains 
during routine diagnostic practice, are in line with published data, [73] [74] and mainly 
they confirmed our hypothesis that use of MALDI-TOF spectra analysis for 
detection of the 11,109Da peak could be relevant to our routine screening. Indeed, 
we analyzed a consistent number of strains, and we only found 2% false negative 
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(8/362) and none false positive. Since the 8 discrepant strains did not show the peak 
in the spectrum analysis, but were positive to Carba NP test, we propose to use the 
two methods in combination, because we find them complementary, so as not to 
miss other possible discrepant strains.  
The correlation between the presence of 11,109Da peak and positive results 
by Carba NP test confirmed the reliability of MALDI-TOF MS analysis as rapid 
screening method of KPC-producing bacterial strains.  
Epidemiology of our geographic area, with over 90% of carbapenemase 
which are KPC, [Graph. 7] is favourable to implement this analysis. The utility of 
the 11,109Da peak detection, moreover, is not only direct to find KPC-producing 
strains during the routine identification, but also to find strains producing other 
types of carbapenemases, for example NDM or VIM which are also increasing in 
frequency, or new carbapenemases. The presence of the 11,109Da peak combined 
with a positive Carba NP test confirms KPC production. On the other hand, the 
absence of the peak combined with positive Carba NP test can lead to perform PCR 
for bla genes and to search for carbapenemase other than KPC. In fact, the 3 strains 
above mentioned, were detected and characterized as NDM and VIM producers 
exactly through spectra analysis, since the Carba NP test provide information only 
about carbapenemase production, but not about the type of carbapenemase 
involved. This is important not only to provide epidemiologic information, but 
mostly, to detect strains with high level of resistance and transmissibility like NDM 
producers, the new threat emerging worldwide. Also, detailed information about 
the specific type of carbapenemase is important when a therapy effective against 
only some specific types of carbapenemase producers is required, like with 
Ceftazidime-Avibactam which is not active against MBL producer strains. [104]  
 
The peak of 11,109Da was detected in 2014 by Lau and coll. [73] who were 
investigating 18 KPC-producing K. pneumoniae strains from an outbreak. They 
proved the peak to be present only in KPC-producing strains and which they 
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supposed to correspond to a product of blaKPC gene, adjacent to Tn4401, carried on 
plasmid pKpQIL. [73]  
Later, the same group proved the 11,109da peak to be corresponding to a 
protein named p019 not to KPC. [74] The gene codifying for this protein, however is 
associated with some type of plasmid harboring KPC gene too. In fact, they detected 
the 11,109Da peak in spectra of carbapenemase-resistant strains, positive for KPC 
and for p019. The presence or the absence of the peak is therefore related with the 
presence or absence of the gene of p019 protein and therefore with the transposon 
and with the type of plasmid harbored KPC gene, not directly with KPC. [74] In over 
90% of the KPC producer strains, blaKPC and p019 genes are associated, carried 
simultaneously on pKpQIL plasmid.  
In 2016, Gaibani and coll., demonstrated that the p019 gene was associated 
with transposon Tn4401a isoform [105] as part of an Insertion Sequence present only 
in plasmid harboring KPC gene. [106] Probably, in discrepant strains, different 
mobile elements carry blaKPC gene, without harboring p019 gene. 
Then, these studies indicate a strong association between the 11,109Da peak 
(corresponding to p019 protein) and KPC production, reporting a small percentage 
of discrepant strains.  
Our results too, confirmed that the presence of the 11,109Da peak is 
correlated with KPC, depending on the type of plasmid harboring blaKPC gene. In 
our analysis, the 11,109Da peak is present in strains carrying the p019 gene in 
IncFII type plasmid, and absent in strains not carrying the p019 gene and harboring 
other plasmids. [Tab. 31] That it is explained with epidemiological data. In our 
region, that is, the prevalent KPC sequence type is ST258, spread worldwide. [82] 
This clonal strain harbors different plasmids, the most frequent being pKpQIL, 
which carries the transposon Tn4401 and belonging to Inc group FII. [52] [57] These 
strains seem to be the same carrying the p019 gene and therefore, those detectable 
as KPC producers through the 11,109Da peak. The percentage of strains harboring 
other mobile genetic elements different from pKpQIL plasmid, carrying blaKPC 
gene, but not p019 gene and therefore not detectable through the 11,109Da peak 
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appear to be very few. In our strains, however, the Tn4401 gene shows no strong 
correlation with the p019 gene and 11,109Da peak, because it is observed in both 
groups of strains (discrepant and control strains), and this requires further 
evaluation. 
The peak searching is a screening method which is sensitive, speciﬁc, it 
provides immediate useful information to clinicians, allowing them to adopt prompt 
containing measures for carriers, because it is very rapid, simple to perform, does 
not require much expertise, nor extra steps on top of ordinary identification by 
MALDI-TOF MS system. Moreover, the costs are much lower compared to other 
diagnostic tests, like for example molecular methods, which are also time-
consuming, more difficult to perform and their use could be then restricted for 
discrepant strains only. 
Other advantages of this sort of analysis are the followings: the MALDI-
TOF MS measurements can be performed directly from colony, by more than one 
operator and they can be used for screening of a large number of samples. Peak 
detection can be performed also retrospectively, on spectra already acquired for 
identification, whenever there is a need to confirm a diagnostic suspect or on spectra 
of strains isolated from samples not send for screening and therefore following 
longer diagnostic procedures, rapidly identifying the potential presence of KPC 
producers. 
To ensure reliable results, it is extremely important to acquire high quality 
spectra (confidence ≥90%). Therefore, it is necessary to guarantee for calibration 
of the instrument and for standardization of the pre-analytical phase, culturing the 
bacterial strains on the same type of plate, under the same conditions. 
 It would be desirable and very useful, however, to have the chance to rely 
on a software able to automatically spot the presence or absence of the 11,109Da 
peak. 
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Part II – In the second part of this study, we tried to find new characteristic 
MALDI-TOF MS peaks corresponding to carbapenemase other than KPC: NDM 
and VIM. Isolation of strains producing these enzymes, in fact, is arising in our 
region, too.  
For this purpose, we used well-characterized strains from collection, namely 
15 NDM-producing Enterobacteriaceae and 36 VIM-producing strains (23 
Enterobacteriaceae and 13 P. aeruginosa). [Fig. 28] After acquiring their MALDI-
TOF MS spectra, we used them to create two superspectra, one for NDM producers 
and the other for VIM producers. Through the superspectra we wanted to select a 
few peaks present only in spectra of resistant-strains, excluding the masses common 
to susceptible strains. In a second step, we tried to find a peak common to all 
resistant strains NDM-producing and VIM-producing respectively, but we did not 
find any specific peak. 
Afterwards, we performed plasmid characterization only for Enterobacteria 
strains, so as to classify the strains by frequency of plasmids, because we supposed 
that the peak searched could be common not to all strains, but to strains harboring 
a certain plasmid. In the NDM group we observed that the most represented 
plasmids are A/C (6/15), OriColE (6/15) and IncR (5/15); in VIM group, they are 
A/C (12/23), L/M (9/23), OriColE (8/23) and IncR (5/23).  [Tab. 34 and 35]  
Then, we divided the strains in groups based on plasmid and repeated 
manually the spectra analysis, but also this way we found no common peak. 
This result can be explained with a greater variability in plasmid harboring 
blaNDM and blaVIM, compared to plasmid carrying blaKPC. It also could indicate that 
there is not such a thing as a single protein being associated with a detectable peak 
in MALDI-TOF spectra corresponding to NDM and VIM producer strains. 
Since we could not find any new peak yet, we can adopt the same 11,109Da 
peak detection in order to have an indication about strains producing 
carbapenemase other than KPC, as explained above, if a positive Carba NP test 
does not correspond to presence of the peak.  
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Part III – In the third and last part of our study, we investigated the use of 
MALDI-TOF MS system to type bacterial strains during hospital outbreaks. In 
literature, most of the studies were performed with MALDI-TOF MS system of 
Bruker Daltonics producer, as far as we know no study was performed with the 
MALDI-TOF MS system bioMérieux in use in our laboratory. 
 To perform this part of the study, we used a group of 44 K. pneumoniae 
strains isolated from clinical samples during an outbreak in ICU from January to 
March 2015. [Tab. 36] 
For all strains, we confirmed the identification by MALDI-TOF MS system 
and carbapenemase production by PCR for blaKPC gene. Then, we acquired the 
spectra to perform an analysis and generate a dendrogram. This step is rapid and 
performed automatically, obtaining relative or absolute taxonomy. We chose to use 
relative taxonomy that generates a dendrogram based on percentage similarity, [Fig. 
40] while the absolute taxonomy shows the coincident masses number. 
 As control, we performed the PFGE on the same strains, analyzed the 
pattern of DNA by FPQuest™ Software, and thus obtained a dendrogram. [Fig. 42] 
 Finally, we compared the results of MALDI-TOF MS spectra analysis and 
PFGE. 
Our results were clearly different according to the two system. The 
dendrogram generated by PFGE was easier to read than the dendrogram of MALDI-
TOF MS. The strains correlated, included in a cluster in PFGE dendrogram, were 
early detectable, unlike in MALDI-TOF MS taxonomy. Moreover, we obtained 
discrepant results, because, for example, strains identical in PFGE analysis 
(similarity 97% or 100%) seems lightly related in MALDI-TOF MS taxonomy 
(similarity ~70%) and strains totally unrelated for PFGE analysis (similarity 40%) 
show the same percentage of similarity (~70%) as related strains. [Fig. 40 and 
following] Also, our results, are different from most published data, showing 
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comparable results with PFGE and propose the use of MALDI-TOF MS to type 
bacterial strains. [76] [77] 
 In our study, the difference between the two systems seems very important. 
We repeated the analysis also on separate groups of strains according to the clusters 
generated by DNA patterns analysis, but also this way the difference was still 
confirmed.  
It is necessary to clarify if the difference in results is intrinsic to the systems 
(since PFGE compares DNA fragments and MALDI-TOF MS compares masses) 
or if it is a problem based on different cut-off and/or the software used by MALDI-
TOF MS system.  
PFGE is the Gold Standard for bacterial strains typing, especially during 
outbreaks. [99] [107] [108] It is based on DNA fragments analysis, obtained through 
Enzyme of Restriction, separated by pulsed-electrophoresis and shown as band. The 
profile analysis can be performed visually or automated and there are guidelines for 
interpretation. [109] For dendrogram interpretation there is percentage similarity cut-
point. [98] The PFGE is very useful, but it has the disadvantages that it is very time-
consuming, is not easy to perform and it needs equipment and expertise. The use of 
MALDI-TOF MS spectra analysis to typing bacterial strains could be very useful 
in terms of time-saving, costs containment and easiness of performance. Our 
results, however, were not very promising. 
 Our study confirmed that PFGE is an assay with higher performances. The 
evaluation offered through MALDI-TOF MS to clustering with the software 
currently in use seems little understandable and hard to interpret. 
 Extremely important for this analysis is the high quality of the spectra 
(confidence ≥90%) and the homogeneous consistency concerning similar number 
of peaks (>170) so as to guarantee a correct comparison among the spectra, and 
allow for reliable results. 
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 In conclusion, in this study we confirmed the strong correlation between 
KPC production and the presence of the 11,109Da peak in MALDI-TOF MS 
spectra in a large number of samples. We also demonstrated that it is very easy to 
perform spectra analysis to detect the 11,109Da peak and it would be very 
convenient to introduce it in diagnostic routine workflow.  
This system is suitable for a context like our region, where KPC is endemic 
and represents over 90% of the carbapenemases detected and can be used to search 
for other carbapenemases, too, since at this moment we have not found any other 
characteristic peak specific to NDM and VIM production. 
And yet, it is evident this method cannot substitute susceptibility test. 
MALDI-TOF MS spectra analysis combined with Carba NP test can provide very 
quickly, adjunctive information to clinicians, but if performed without further 
results, it is not sufficient to diagnose carbapenemase production on its own.  
Since we observed the correlation between p019 gene and 11,109Da peak, 
in a small number of strains (8 control strains), [Tab. 31] in the future, we are going 
to further investigate other discrepant strains and hopefully confirm the presence or 
absence of p019 and Tn4401 genes related with the 11,109Da peak in MALDI-TOF 
MS spectrum on a larger number of strains. 
 Finally, at this moment, the use of MALDI-TOF MS system (bioMérieux) 
to rapidly typing epidemic strains is not viable yet, and cannot substitute the Gold 
Standard PFGE. It needs more investigations to this purpose, and it would be useful 
to improve the software for spectra analysis and dendrogram generation. 
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